Phase II study

Patient	Treatment group	Visit

BL	C2D1	C3D1	C4D1	D85	D180	D360	ET

1	Lipegfilgrastim	Neg	Neg	Neg	Neg	Pos	NA	NA	NA

2	Lipegfilgrastim	NA	NA	NA	NA	NA	NA	Pos	NA

3	Lipegfilgrastim	Pos	Pos	Pos	Pos	Pos	Pos	Pos	NA

4	Lipegfilgrastim	Pos	Pos	Pos	Pos	Pos	Pos	Neg	NA

5	Lipegfilgrastim	Pos	Pos	NA	NA	NA	Pos	Pos	Neg

6	Lipegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

7	Lipegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

8	Lipegfilgrastim	Pos	NA	NA	NA	NA	NA	Neg	NA

9	Lipegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

10	Pegfilgrastim	NA	NA	NA	NA	Pos	NA	NA	NA

11	Pegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

12	Pegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

Phase III study

Patient	Treatment group	Visit

S	BL	C2D1	C3D1	C4D1	D85	D180	D360

13	Lipegfilgrastim	NA	NA	NA	NA	NA	NA	Pos	Pos

14	Lipegfilgrastim	NA	Pos	Pos	Pos	Pos	Neg	Neg	Neg

15	Lipegfilgrastim	NA	Pos	Pos	Neg	Neg	Neg	Neg	Neg

16	Lipegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA

17	Pegfilgrastim	NA	NA	NA	NA	NA	NA	NA	Pos

18	Pegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA

19	Pegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

20	Pegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA

21	Pegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA

22	Pegfilgrastim	NA	Pos	Neg	NA	NA	NA	NA	NA

23	Pegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA

Phase II study

Patient	Treatment group	Visit

BL	C2D1	C3D1	C4D1	D85	D180	D360	ET

18	Pegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA

19	Pegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

20	Pegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA

21	Pegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA

22	Pegfilgrastim	NA	Pos	Neg	NA	NA	NA	NA	NA

23	Pegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA


mRNA co-expression MET vs.	ALL Stage	Stage I-II	Stage III-IV

Pearson's Correlation	p-value	Pearson's Correlation	p-value	Pearson's Correlation	p-value

ALDH1A1	0.06	0.008	0.05	0.058	-0.03	0.736

ALDH1A3	0.22	<0.001	0.21	<0.001	0.40	<0.001

CD44	0.02	0.381	0.01	0.857	0.04	0.637


Main objectives of participating in the training	n	%

To learn about psychosomatic medicine/biopsychosocial models	28	25%

To learn didactical teaching methods (such as interactive learning and presenting lectures)	23	20%

To acquire practical skills for daily clinical practice (such as communication, role playing, patient interviewing, family interviewing, and creating genograms)	18	16%

To learn about doctor-patient communication skills	12	11%

To improve patient management	9	8%

To learn about the diagnosis and treatment of specific psychosomatic disorders	8	6%

To address administrative and sustainability issues in the curriculum	5	4%

To learn how to use Balint group methods	5	4%

To share experiences with other doctors/acquire more self-experience	4	3%

Other	2	2%

Main objectives of participating in the training	n	%

To learn about the diagnosis and treatment of specific psychosomatic disorders	8	6%

To address administrative and sustainability issues in the curriculum	5	4%

To learn how to use Balint group methods	5	4%

To share experiences with other doctors/acquire more self-experience	4	3%

Other	2	2%


	Intervention, n = 114	Comparison, n = 60

IPV status	n	%	n	%

0	9	8	6	10

3–6	11	10	2	3

≥ 7	93	82	48	80

Missing	1	1	4	7

When partner last inflicted abuse

 Abused in last 12 months(n = 121)

0	1	1	0	0

3–6	3	4	1	2

≥ 7	76	95	39	95

Missing	0	0	1	2

 Abused>12 months ago (n = 33)

0	4	20	3	23

3–6	3	15	0	0

≥ 7	13	65	8	62

Missing	0	0	2	15

 A partner has never abused me(n = 15)

0	4	36	2	50

3–6	2	18	1	25

≥ 7	4	36	0	0

Missing	1	9	1	25

Depressed (EPDS ≥ 13)

No	32	28	26	43

Yes	81	71	33	55

Missing	1		1


Item	Patient Ratings	Clinician Ratings

	Localized	Metastatic	Total	Nurse	Physician	Total

PAIN

 I have pain	2.4	1.8	2.1	3.8	4.0	3.9

 Pain interfered with my daily activities	2.0	1.8	1.9	3.8	3.2	3.5

 I have pain in my back	2.0	1.1	1.5	2.4	2.6	2.5

 I have discomfort or pain in my stomach area	1.7	1.8	1.8	2.6	1.8	2.2

BREATHING

 I have been short of breath	0.7	2.5	1.7	3.8	3.0	3.3

WEAKNESS

 I have felt weak	2.2	2.8	2.5	4.0	3.6	3.8

MOOD

 I worry that my condition will get worse	3.0	3.1	3.1	3.6	2.4	3.0

 I have emotional ups and downs	2.6	2.2	2.4	3.6	1.6	2.6

 I feel depressed	2.6	2.0	2.3	3.6	1.8	2.7

 I am able to enjoy life2	2.2	2.8	2.5	3.8	3.0	3.4

SLEEP

 I have had trouble sleeping	2.5	2.1	2.3	3.6	2.4	3.0

WEIGHT LOSS

 I am losing weight	1.4	2.0	1.7	3.5	3.6	3.6

COGNITIVE

 I have difficulty remembering things	1.6	1.6	1.6	3.5	2.0	2.7

 I have trouble concentrating	1.7	2.1	1.9	3.5	2.0	2.7

FATIGUE

 I feel fatigued	2.3	2.0	2.2	3.8	3.8	3.8

 I have a lack of energy	2.4	2.5	2.5	3.8	3.2	3.4

 I feel tired	2.3	2.1	2.2	3.8	3.0	3.3

 I have trouble starting things because I am tired	1.7	2.1	1.9	3.0	2.0	2.5

 I have trouble finishing things because I am tired	1.9	2.4	2.2	3.0	2.0	2.5

APPETITE

 I have lacked appetite	1.5	1.9	1.7	3.6	3.6	3.6

 I have a good appetite3	2.5	3.1	2.8	3.0	3.4	3.2

INCONTINENCE (BOWEL OR BLADDER)

 I have control of my bowels4	2.4	2.5	2.5	2.2	1.6	1.9

 I have trouble moving my bowels	1.6	1.3	1.5	3.6	2.2	2.9

 I urinate more frequently than usual5	1.7	1.7	1.7	2.2	1.6	1.9

 I have difficulty urinating	1.6	1.2	1.4	2.4	1.6	2.0

OTHER SYMPTOMS

 I have had chills	1.4	1.8	1.6	3.4	2.6	3.0

 I have had fevers	1.3	1.5	1.4	3.8	3.0	3.4

 I have had sweats6	1.2	1.1	1.1	3.8	3.2	3.5

 I feel lightheaded	1.6	1.7	1.6	2.8	2.6	2.7

 I am bothered by blood in my urine7	n/a	n/a	n/a	2.0	2.8	2.4


Target genes	Primers

MMP1	Forward primer: 5′-aagccatcacttaccttgcact-3′

	Reverse primer: 5′-tcagagaccttggtgaatgtca-3′

MMP9	Forward primer: 5′-ctggagacctgagaaccaa-3′

	Reverse primer: 5′-actgctcaaagcctccacaaga-3′

β-Actin	Forward primer: 5′-ctccatcctggcctcgctgt-3′

	Reverse primer: 5′-gctgtcaccttcaccgttcc-3′

Target genes	Primers

	Reverse primer: 5′-tcagagaccttggtgaatgtca-3′

MMP9	Forward primer: 5′-ctggagacctgagaaccaa-3′

	Reverse primer: 5′-actgctcaaagcctccacaaga-3′

β-Actin	Forward primer: 5′-ctccatcctggcctcgctgt-3′

	Reverse primer: 5′-gctgtcaccttcaccgttcc-3′


Metal	SQGs (mg/kg)-Freshwater Sediment (Upstream)	Percentage of Samples Exceeding SQGs (%)

TEL	PEL	<TEL	TEL-PEL	>PEL


Factor	Cronbach’s α	Item-to-subscale correlation	Subscale-to-total correlation

1 Psychological expression	0.92	0.58–0.75	0.92

2 Changes in self and family	0.82	0.49–0.62	0.73

3 Physical symptoms	0.81	0.31–0.64	0.80

4 Social and family connectedness	0.73	0.30–0.73	0.39

5 Fatalism	0.88	0.67–0.84	0.39

6 Religion and faith	0.64	0.17–0.66	0.02

7 Self-query	0.62	0.27–0.47	0.59

8 Coping style	0.59	0.34–0.50	0.12


	Transobturator Sling	Single-Incision Sling	p value

Preoperative daily pads usage (mean)	4.45±0.82 (3-6)	4.25±0.78 (3-6)	p=0.495

Postoperative daily pads usage (mean)	0.30±0.57 (0-2)	0.55±0,68 (0-2)	p=0.192

Postoperatively, the number of patients with	15 / 20	11 / 20	p=0.190

no pad usage (n / all patients)

Subjective cure rates	75%	55%	p=0.190


Treatment options	Mean cost per child in A$2010-2011 (95%CI)	Mean number of QALYs (95%CI)	Mean incremental number of QALYs vs no treatment	ICER

No treatment	0	11.57	-	-

		(10.24; 13.06)

Non-directive 	21	12.59		20


	Total dust	Respirable crystalline silica dust

Long-term average exposure (mg/m3)

Mean (SD)	6.1 (4.8)	0.27 (0.19)

Median (min.–max.)	4.8 (0–36.7)	0.22 (0–1.16)

Highest exposure ever* (mg/m3)

Mean (SD)	23.5 (11.6)	0.73 (0.34)

Median (min.–max.)	23.8 (0–65.8)	0.74 (0–1.95)

Cumulative exposure (mg/m3-year)

Mean (SD)	226.4 (171.0)	7.32 (5.22)

Median (min.–max.)	183.7 (0–861.7)	6.20 (0–26.6)

Exposure duration (years)

Mean (SD)	27.8 (7.4)

Median (min.–max.)	27.8 (1.1–46.4)

	Total dust	Respirable crystalline silica dust

Highest exposure ever* (mg/m3)

Mean (SD)	23.5 (11.6)	0.73 (0.34)

Median (min.–max.)	23.8 (0–65.8)	0.74 (0–1.95)

Cumulative exposure (mg/m3-year)

Mean (SD)	226.4 (171.0)	7.32 (5.22)

Median (min.–max.)	183.7 (0–861.7)	6.20 (0–26.6)

Exposure duration (years)

Mean (SD)	27.8 (7.4)

Median (min.–max.)	27.8 (1.1–46.4)


 	Qigong	Exercise therapy	Study population

 	Mean (±SD)	Mean (±SD)	Mean (±SD)

 	N = 10 8 female, 2 male	N = 10 8 female, 2 male	N = 122 107 female, 25 male

Age (years)	40.6 (±10.3)	44.6 (±9.3)	45.6 (±10.7)

VAS baseline (mm)	60.1 (±13.1)	56.5(±12.2)	56.2 (±14.1)

Pain duration (years)	3.9 (±1.2)	3.1 (±1.6)	3.2 (±1.6)

	Qigong	Exercise therapy

	Mean (±SD)	Mean (±SD)

	N = 10 8 female, 2 male	N = 10 8 female, 2 male

Age (years)	40.6 (±10.3)	44.6 (±9.3)

VAS baseline (mm)	60.1 (±13.1)	56.5(±12.2)

Pain duration (years)	3.9 (±1.2)	3.1 (±1.6)


General descriptives	∑ Tot.	Sand	Canopy-forming algae	Seagrass aboveground	Seagrass belowground

Traditional numerical variables

# of species 	36	17	26	29	23

# of species only in one habitat	10	2	4	3	1

# of species found in all habitats	13

Abundance dm-3 (Mean ± SD)		18.4±11.5	2733.8±1624.8	5974.7±4154.3	110.0±44.2

Functional variables

# of modalities expressed (Total)	55	51	55	54	53

# of modalities (Mean ±SD)		44.3±3.1	48.5±1.8	50.6±3.4	51.7±1.1

# of species per modality (Mean)		2.4	3.7	4.5	4.2

General descriptives	∑ Tot.	Sand	Canopy-forming algae	Seagrass aboveground	Seagrass belowground

al variables

# of modalities expressed (Total)	55	51	55	54	53

# of modalities (Mean ±SD)		44.3±3.1	48.5±1.8	50.6±3.4	51.7±1.1

# of species per modality (Mean)		2.4	3.7	4.5	4.2


 	Shift admitted	p value

 	Day	Night

Mortality (%)	3.5	4.3	0.57

ICU admission (%)	2.2	3.2	0.32

Mean length of stay (days)	5.1	5.7	0.18∗

Readmission, 30 days (%)	8.1	7.1	0.60

Need for surgery (%)	43.5	39.6	0.26

	Shift admitted

	Day

Mortality (%)	3.5

ICU admission (%)	2.2

Mean length of stay (days)	5.1

Readmission, 30 days (%)	8.1

Need for surgery (%)	43.5


Origin	Region	Isolate serial number	Total number of isolates	Number of genotypes	Number of polymorphic loci	Polymorphic loci (%)

Rich Kser Wallal	Rich Errachidia	7	1	-	-	-

Rich Kser Aït Said	Rich Errachidia	20	1	-	-	-

Rich Kser Tabia	Rich Errachidia	27; 30	2	-	5	13.51

Demnate	Demnate	42	1	-	-	-

Ziz Kser Bouya Jerf	Jerf Erfoud	57-58	2	-	6	16.22

Jerf	Jerf Erfoud	66	1	-	-	-

Erfoud Hay Lagmbita	Jerf Erfoud	76-80; 88	6	6	20	54.05

Erfoud Masoudia	Jerf Erfoud	91-92	2	-	5	13.51

Errachidia Aïne Zerka	Rich Errachidia	116-117	2	-	9	24.32

Toudra Tinghir	Tinghir	119; 121	2	-	14	37.84

Ziz Errachidia	Ziz	122	1	-	-	-

Over all	-	-	21	21	35	94.59


HCC parameters	Number of patients	miR-940 (−)	miR-940 (+)	χ2	P

Gender

 Male	38	31	7	0.515	0.473

 Female	8	5	3

Age

 ≥50 years old	36	29	7	0.080	0.777

 <50 years old	10	7	3

Etiology

 HBV+	38	30	8	0.000	1.000

 HBV−	8	6	2

Cirrhosis

 Positive	37	31	6	1.934	0.164

 Negative	9	5	4

AFP (ng/mL)

 ≥400	29	22	7	0.021	0.885

 <400	17	14	3

Tumor size

 ≥5 cm	26	21	5	0.012	0.913

 <5 cm	20	15	5

TNM stage

 I-II	25	18	7	0.584	0.445

 III-IV	21	18	3

Edmondson grade

 I-II	22	13	9	7.076	0.008∗∗

 III-IV	24	23	1

Tumor microsatellite or multiple tumors

 Yes	20	19	1	4.217	0.040∗

 No	26	17	9

Vascular invasion

 Yes	15	15	0	4.432	0.035∗

 No	31	21	10

Recurrence and metastasis

 Yes	29	26	3	4.313	0.038∗

 No	17	10	7


Target protein or pathway	Drug	CHIKV IC50 (μM)	WST-1 IC50 (μM)	Therapeutic index

Fatty acid synthesis	TOFA	0.15	> 60*	NT

 	Orlistat	0.82	8.67	10.57

 	Cerulenin	3	7.57	2.53

vATPase	Bafilomycin	0.000334	0.003*	NT

CLK1	AnnH18	1.02	9.19	9.04

 	AnnH14	1.55	10.55	6.79

 	KH-CB19	3.36	10.93	3.26

KAT5	(15:3)-Anacardic acid	0.58	2.68	4.65

Calmodulin signalling	TAE684	0.15	2.07	14.28

 	Pimozide	0.28	19.18	69.75

 	Perphenazine	0.63	24.23	38.28

 	6-Hydroxyflavone	2.6	> 60	NT

 	Prenylamine	2.39	16.53	6.91

 	Felodipine	3.24	12.08	3.73

FLT4	Alsterpaullone	0.002	44.38*	NT

 	Pazopanib	0.13	1.32*	NT

 	Axitinib	0.3	0.34*	NT

 	Tivozanib	0.8	8.34*	NT

 	Sorafenib	1.11	18.24	16.42

 	Linifanib	2.15	> 60	NT

Target protein or pathway	Drug	CHIKV IC50 (μM)	WST-1 IC50 (μM)	Therapeutic index

	Prenylamine	2.39	16.53	6.91

	Felodipine	3.24	12.08	3.73

FLT4	Alsterpaullone	0.002	44.38*	NT

	Pazopanib	0.13	1.32*	NT

	Axitinib	0.3	0.34*	NT

	Tivozanib	0.8	8.34*	NT

	Sorafenib	1.11	18.24	16.42

	Linifanib	2.15	> 60	NT


Name BRE	5′ primer (5′-3′)	3′ primer (5′-3′)	size (bp)

7–13	GATGAGCTCATGCGAAAGTGAAGGTGGTCCCCAG	TGAAGATCTAGCAAGGAGGAACTGGAGATGTCA	1278

9–13	GAGCTCTCGAACCTCTCTTTCCTATCTC	AGATCTAGCAAGGAGGAACTGGAGATGTCA	695

10–13	GAGCTCTGGAGCTGAGCCTGGAGAGAAG	AGATCTAGCAAGGAGGAACTGGAGATGTCA	530

12–13	GAGCTCTAGGCCATCAGACAGCTCTGAG	AGATCTAGCAAGGAGGAACTGGAGATGTCA	127

9	GAGCTCTCGAACCTCTCTTTCCTATCTC	AGATCTCTTCTCTCCAGGCTCAGCTCCA	189

9–10	GAGCTCTCGAACCTCTCTTTCCTATCTC	AGATCTCCCTCATCTCTCCTTGCAGCT	253

9–11	GAGCTCTCGAACCTCTCTTTCCTATCTC	AGATCTAGGCCCTCAAATTCCTCAGAG	348

5′ primer (5′-3′)	3′ primer (5′-3′)	size (bp)

GATGAGCTCATGCGAAAGTGAAGGTGGTCCCCAG	TGAAGATCTAGCAAGGAGGAACTGGAGATGTCA	1278

GAGCTCTCGAACCTCTCTTTCCTATCTC	AGATCTAGCAAGGAGGAACTGGAGATGTCA	695

GAGCTCTGGAGCTGAGCCTGGAGAGAAG	AGATCTAGCAAGGAGGAACTGGAGATGTCA	530

GAGCTCTAGGCCATCAGACAGCTCTGAG	AGATCTAGCAAGGAGGAACTGGAGATGTCA	127

GAGCTCTCGAACCTCTCTTTCCTATCTC	AGATCTCTTCTCTCCAGGCTCAGCTCCA	189

GAGCTCTCGAACCTCTCTTTCCTATCTC	AGATCTCCCTCATCTCTCCTTGCAGCT	253

GAGCTCTCGAACCTCTCTTTCCTATCTC	AGATCTAGGCCCTCAAATTCCTCAGAG	348


Outcomes	Group	LS mean ± SEa	Differenceb (95 % CI)	P-value

Primary outcome

Total VSCs

10 min	Test	0.115 ± 0.078	−0.246	0.002

Placebo	0.362 ± 0.081	(−0.395 to 0.098)

30 min	Test	0.173 ± 0.086	−0.136	0.1

Plac	0.30	(−0.348 to 0.075)


Dependent variable	Independent variable	Estimate	Standard error	95% CI	P

SF-BP	Migraine (yes vs. no)	−8.93	1.40	−6.20 to −11.67	<0.001

HAMD (one-point increment)	−1.20	0.10	−1.00 to − 1.40	<0.001

HADS-A (one-point increment)	−0.59	0.19	−0.22 to −0.96	<0.01

Educational years (one-year increment)	0.90	0.29	1.47 to 0.32	<0.01

PS	Migraine (yes vs. no)	1.33	0.23	1.78 to 0.89	<0.001

HAMD (one-point increment)	0.19	0.02	0.22 to 0.16	<0.001

HADS-A (one-point increment)	0.12	0.03	0.18 to 0.06	< 0.001

Educational years (one-year increment)	−0.13	0.05	−0.03 to −0.23	0.01

Married (yes vs. no)	0.53	0.21	0.95–0.12	0.01

Age (one-year increment)	0.03	0.01	0.05 to 0.004	0.02

Anxiety disorders (yes vs. no)	0.52	0.24	1.00 to 0.05	0.03

SF-BP	HADS-A (one-point increment)	−0.59	0.19	−0.22 to −0.96	<0.01

Educational years (one-year increment)	0.90	0.29	1.47 to 0.32	<0.01

PS	Migraine (yes vs. no)	1.33	0.23	1.78 to 0.89	<0.001

HAMD (one-point increment)	0.19	0.02	0.22 to 0.16	<0.001

HADS-A (one-point increment)	0.12	0.03	0.18 to 0.06	< 0.001

Educational years (one-year increment)	−0.13	0.05	−0.03 to −0.23	0.01

Married (yes vs. no)	0.53	0.21	0.95–0.12	0.01

Age (one-year increment)	0.03	0.01	0.05 to 0.004	0.02

Anxiety disorders (yes vs. no)	0.52	0.24	1.00 to 0.05	0.03


Coal samples	Atomic concentration of elements/%	(O/C) ratio/%

C 1s	O 1s	N 1s	S 2p	Elemental analysis	XPS analysis

Beizao lignite	80.34	18.22	1.44	/	20.61	22.68

Daliuta long flame coal	84.37	14.17	0.94	0.52	16.02	16.80

Yushuwan gas coal	87.68	11.5	0.82	/	12.03	13.12

Xinjulong fat coal	89.11	8.88	1.72	0.29	7.15	9.97

Wugou coking coal	88.41	9.08	1.83	0.68	5.50	10.27

Yangquan anthracite	89.18	9.05	1.34	0.43	2.52	10.15

Coal samples	Atomic concentration of elements/%	(O/C) ratio/%

C 1s	O 1s	N 1s	S 2p	Elemental analysis	XPS analysis

Daliuta long flame coal	84.37	14.17	0.94	0.52	16.02	16.80

Yushuwan gas coal	87.68	11.5	0.82	/	12.03	13.12

Xinjulong fat coal	89.11	8.88	1.72	0.29	7.15	9.97

Wugou coking coal	88.41	9.08	1.83	0.68	5.50	10.27

Yangquan anthracite	89.18	9.05	1.34	0.43	2.52	10.15


Variable	N	R Pearson Correlation	Level of significance

Organizational culture and organizational commitment	165	0.419	0.027


Variable	b

Unreasonable illegitimate Tasks	0.53*

Role Conflict	0.08

Control over Work Pace	−0.44**

Exhaustion	0.59**

Administrative Tasks	0.004

Gender	0.02

Age	−0.07

-2log likelihood 619.37**Cox & Snell R2 .107Nagelkerke R2 .144


RSV	Influenza A (H1N1) virus

Age <6 months	Age <5 years

History of prematurity	Chronic lung disease

Chronic lung disease	Congenital heart disease

Congenital heart disease	Immunocompromised conditions

Viral coinfection


Group	Sub group	Gender	Age (years ± SD)	Verbal memory (score ± SD)	O&M (years ± SD)

Gamers	Early blind	4 m/4 f	24.00 ± 6.76	81.13 ± 15.29	14.25 ± 7.78

	Late blind	5 m/2 f	29.86 ± 7.34	72.43 ± 18.16	1.0 ± 0.00*

	Subgroup totals/means	9 m/6 f	26.73 ± 7.42	77.07 ± 16.69	8.07 ± 8.78

Directed navigators	Early blind	4 m/3 f	28.29 ± 9.05	87.86 ± 6.82	10.43 ± 9.91


Sensory neurons in the DRGs	BL40	GB30

Large-sized neuron	58 (10.78%)	149 (17.21%)

Medium-sized neuron	222 (41.26%)	357 (41.22%)

Small-sized neuron	258 (47.96%)	360 (41.57%)


		Number	Percent

Gender	Female	379	90.9

Male	38	9.1

Country	Australia	396	94.9

New Zealand	21	5.1

Age (years)	21-30	23	5.5

31-40	84	20.1

41-50	156	37.4

51-60	141	33.8

60+	13	3.1

Length of Time Working in Haemodialysis	<1 year	11	2.6

1-2 years	22	5.3

3-5 years	70	16.8

6-10 years	116	27.8

11-15 years	94	22.5

16-20 years	41	9.8

>20 years	63	15.1

Nursing Classification	Registered Nurse (RN)	406	97.4

Enrolled Nurse (EN)	11	2.6

Highest Nursing Qualification	Certificate in Nursing	85	20.4

Diploma in Nursing	56	13.4

Undergraduate Degree	74	17.7

Postgraduate Certificate/Diploma	170	40.8

Masters/Doctorate	32	7.7

Work Location	Metropolitan	177	42.4

Regional	144	34.5

Rural	85	20.4

Remote	11	2.6

Type of Unit	In-Center	187	44.8

Satellite	202	48.4

Home	28	6.7

		Number	Percent

Length of Time Working in Haemodialysis	11-15 years	94	22.5

16-20 years	41	9.8

>20 years	63	15.1

Nursing Classification	Registered Nurse (RN)	406	97.4

Enrolled Nurse (EN)	11	2.6

Highest Nursing Qualification	Certificate in Nursing	85	20.4

Diploma in Nursing	56	13.4

Undergraduate Degree	74	17.7

Postgraduate Certificate/Diploma	170	40.8

Masters/Doctorate	32	7.7

Work Location	Metropolitan	177	42.4

Regional	144	34.5

Rural	85	20.4

Remote	11	2.6

Type of Unit	In-Center	187	44.8

Satellite	202	48.4

Home	28	6.7


Inclusion criteria	Exclusion criteria

Women < 40 years old	Women who conceived the fetus using artificial methods including in-vitro fertilization or intrauterine insemination

Aboriginal ancestry	Women carrying more than one fetus

Pregnant with singleton	Surrogate mothers

 	Women who suffer from severe chronic medical conditions including active cancer, severe infectious diseases including HIV, hepatitis B or C, or who are VDRL positive


Variable	Points

Age >80 years	1

History of cancer	1

History of heart failure or chronic lung disease	1

Pulse rate ≥110 bpm	1

Systolic blood pressure <100 mmHg	1

Oxygen saturation <90 % on room air	1


	Geometric mean

	DEP

Population group	MEP

289 adults (Blount et al. 2000b)	345 (11.4)

2,536 persons 6 to > 20 years of age (Silva et al. 2004a)	163 (5.4)

2,772 persons 6 to > 20 years of age (CDC 2005)	167 (5.5)

85 children and adults (Koch et al. 2003c)a	165b (5.5)


	Description of framework objectives

1.	Surveillance to develop shared operational definitions and determinants of mental illness

2.	Epidemiological research into determinants and protective factors for mental health and their relationships to chronic diseases

3.	Prevention research to determine the importance of mental illness/health as factors in public health promotion and prevention

4.	Communication to develop culturally, linguistically, and developmentally appropriate educational products

5.	Education of Health Professionals including the development of appropriate education plans for professional audiences

6.	Program Integration Support at various jurisdictional levels

7.	Policy Integration that involves the development of policies at all government levels for all audiences and stakeholders

8.	Systems to Promote Integration such as establish systems integration to promote program and policy integration across multiple infrastructures

Description of framework objectives

Surveillance to develop shared operational definitions and determinants of mental illness

Epidemiological research into determinants and protective factors for mental health and their relationships to chronic diseases

Prevention research to determine the importance of mental illness/health as factors in public health promotion and prevention

Communication to develop culturally, linguistically, and developmentally appropriate educational products

Education of Health Professionals including the development of appropriate education plans for professional audiences

Program Integration Support at various jurisdictional levels

Policy Integration that involves the development of policies at all government levels for all audiences and stakeholders

Systems to Promote Integration such as establish systems integration to promote program and policy integration across multiple infrastructures


Outcome	Regression coefficient(95%CI)

Publication year	Type of fractures

Blood loss	− 0.02 (− 0.11, 0.08)	− 0.70 (− 2.04, 0.64)

Operation time	− 0.32 (− 0.10, 0.04)	− 0.22 (− 1.28, 0.83)


Scale	Fatigue description

1	No such feeling

2	Negligible feeling

3	Some feeling

4	Clear feeling

5	Strong feeling

6	Very strong feeling

7	Extremely strong feeling


C/N0	25 dB-Hz	30 dB-Hz	35 dB-Hz	40 dB-Hz

Standard Receiver	Optimal Bandwidth	15 Hz	22 Hz	28 Hz	35 Hz

Tracking Error of the PLL in Optimal Bandwidth	28 deg.	15 deg.	9 deg.	7 deg.

Dynamic Stress Noise Proportion (BPLL = 20 Hz)	8%	14%	21%	28%

Ultra-tightly Integrated GNSS/INS Receiver	Optimal Bandwidth	7 Hz	9 Hz	13 Hz	25 Hz

Tracking Error of the PLL in Optimal Bandwidth	20 deg.	12 deg.	8 deg.	6 deg.

Dynamic Stress Noise Proportion (BPLL = 20 Hz)	<1%	<1%	<1%	<1%


Characteristic	Number (%)

Male (n = 412)	220 (53)

Role in ED (n = 419)

 Attending	207 (49)

 Resident	170 (41)

 Advanced practice provider	42 (10)

Years working in ED (n = 417)

 < 1 year	52 (13)

 > 1 – < 5 years	164 (39)

 > 5 – < 10 years	53 (13)

 > 10 – < 20 years	85 (20)

 > 20 years	63 (15)

Location of ED* (n = 420)

 Rural	8 (2)

 Suburban	24 (6)

 Urban	410 (98)

ED practice setting* (n = 420)

 Academic	409 (97)

 Community	71 (17)

 VA/military	16 (4)

Prior therapeutic OA use (n=420)	265 (63)


Tissue	Content of poncirin (mg/g FW)

flavedo	0.15 ± 0.01

albedo	1.37 ± 0.09

segment membrane	0.52 ± 0.01

juice sac	0.07 ± 0.01

Tissue	Content of poncirin (mg/g FW)

albedo	1.37 ± 0.09

segment membrane	0.52 ± 0.01

juice sac	0.07 ± 0.01


Problem	Possible Reason	Solution

Genome is not fragmented after sonication.	Buffer condition is not adaptable for sonication.	Purify the DNA. We used QIAGEN PCR Purification Kit, eluted in EB to have it work.

Nothing is visible on the gel after 1 hr electrophoresis during library generation.	When the starting amount of DNA is small or there is significant DNA loss during the process for various reasons, it is possible that the DNA is smeared over a wide range after an hour of electrophoresis and not visible on the gel.	It is good to check the gel to see if the DNA is present after ~10 min run when the DNA is not smeared at a wide range.Even though nothing is visible, it is highly possible that the DNA is still present. Proceed to the next step regardless and see if PCR amplifies anything.

Cannot collect ~400 ul after the stripping step.	Gasket slide was re-used.The array slide was lifted up too quickly.Different buffer was used for the 95C stripping process.	Do not re-use the gasket slide.The solution can be flushed to a collection boat and collected.When using multi-array slides like 2×105 K, 4×44 K or 8×15 K, it is still possible to run the capture protocol as indicated. After the stripping, the array slide should be slowly lifted up to prevent contamination. The solution tends to stay within the gaskets.

Not enough DNA amplified after the first stripping.	Stripping was not efficient.	Another stripping process can be done and checked if there were left over genomic fragments hybridized on the probes. Since it does not matter if the stripped solution contains contaminants as long as the contaminants do not have adapters ligated at the end, it is possible to thoroughly continue the stripping process until no products get amplified.


Dietary Intake Adequacy Based on Mean Adequacy Ratio (MAR)	Minimum Dietary Diversity	Minimum Meal Frequency	Minimum Acceptable Diet	Consumption of Iron-Rich/Fortified Food

Odds Ratio (95% CI)

b MAR > 0.6 (more than 60.0%)	11.10 (3.09, 39.87), p = 0.000	6.70 (1.44, 31.16), p = 0.015	4.03 (1.17, 13.87), p = 0.027	2.73 (0.45, 16.48), p = 0.273

Dietary Intake Adequacy Based on Mean Adequacy Ratio (MAR)	Minimum Dietary Diversity	Minimum Meal Frequency	Minimum Acceptable Diet	Consumption of Iron-Rich/Fortified Food

Odds Ratio (95% CI)

0.5 < a MAR ≤ 0.6 (50.1%–60.0%)	5.49 (1.35, 22.22), p = 0.017	1.60 (0.35, 7.30), p = 0.544	2.96 (0.75, 11.67), p = 0.121	1.33 (0.20, 9.00), p = 0.768


ScheduleTreatment day (TD)Time point (T)	T0 (Screening, baseline and prediagnosis tests)	T1 (Treatment and discharge)	T2 3M	T3 6M	T4 12M	Withdrawal

TD 1*	TD 2	TD 3	TD 4	TD 5	Rescue therapy†	Discharge

Screening with diagnostic algorithm and core investigations including physical examination	X

Patient information and informed consent	X

Eligibility form	X

Registration form	X

Prediagnosis tests—for example, MRI and AQP4	X

Randomisation	X

Biobank samples	X									X

ASIA Impairment Score (A-E)	X						X	X	X	P	X

ASIA Motor and Sensory Score	X						X	X	X	S	X

Neurostatus scoring (Kurtzke functional systems and EDSS)	X							X	X	S	X

8–12 years EQ-5D-Y	X								X	S	X

≥13 years EQ-5D-5L	X								X	S	X

≥13 years SCI QoL Basic data set									X	S	X

CSRI									X	S	X

≥13 years SCI Bladder										T	X

≥13 years SCI Bowel										T	X

5–7 years Peds QL										T	X

2–4 years Peds QL										T	X

Treatment form						X

Concomitant medications								X	X	X	X

Discharge form								X

Rescue therapy form (if needed)†							X

Relapse form (at any time point if needed)†								X	X	X	X

Adverse events‡		X	X	X	X	X

Study Status Form									X	X	X

Withdrawal form (at any time point)†												X

ScheduleTreatment day (TD)Time point (T)	T0 (Screening, baseline and prediagnosis tests)	T1 (Treatment and discharge)	T2 3M	T3 6M	T4 12M	Withdrawal

TD 1*	TD 2	TD 3	TD 4	TD 5	Rescue therapy†	Discharge

5–7 years Peds QL										T	X

2–4 years Peds QL										T	X

Treatment form						X

Concomitant medications								X	X	X	X

Discharge form								X

Rescue therapy form (if needed)†							X

Relapse form (at any time point if needed)†								X	X	X	X

Adverse events‡		X	X	X	X	X

Study Status Form									X	X	X

Withdrawal form (at any time point)†												X


Study	Number of patients	Follow-up (days)	Baseline comparison	Adverse event	Outcomes measure (primary/secondary)	Treatment group dosage	Types of stroke

Cai et al. 2000 [29]	256	14	Y	N	TER, CSS	XNJ 30–60 mL/d + CWM	IS

Chen et al. 2004a [30]	100	14	Y	N	TER	XNJ 20 mL/d + CWM	IS

Chen et al. 2004b [31]	70	14	Y	N	TNF-α, IL-6, IL-1, ESSS	XNJ 40 mL/d + CWM	ICH

Chen 2013 [32]	202	21	Y	Y	NIHSS, IL-9	XNJ 30 mL/d + CWM	ICH

Lei 2013 [33]	120	28	Y	Y	TER	XNJ 20 mL/d + CWM	ICH

Li 2011 [34]	118	14	Y	N	TNF-α, IL-6, NIHSS	XNJ 40 mL/d + CWM	ICH

Liu and Bai 2004 [35]	70	14	Y	N	TNF-α, IL-6, IL-8, ESSS	XNJ 40 mL/d + CWM	ICH/IS

Ming et al. 2010 [36]	91	21	Y	N	ESS,	XNJ 20 mL/d + CWM	ICH

Wang 2013 [37]	155	14	Y	N	TER	XNJ 20 mL/d + CWM	ICH/IS/SAH

Wei and Li 2009 [13]	120	28	Y	Y	TER, CSS	XNJ 10 mL/d + CWM	ICH

Zhang et al. 2012 [38]	65	14	Y	N	NIHSS	XNJ 20 mL/d + CWM	IS

Zhang et al. 2013 [39]	63	14	Y	N	NIHSS	XNJ 20 mL/d + CWM	IS

Zhou et al. 2005 [40]	84	28	Y	N	TER	XNJ 20 mL/d + CWM	ICH


	No Bone Graft(n = 18)	Bone Graft(n = 29)	p value

Pain severity, neck	10.37	17.01	0.139

Pain severity, arm	7.22	6.44	0.628

Functional disability	18.78	21.01	0.877

Psychological distress	19.14	38.37	0.024

Physical symptoms other than neck/arm pain	12.96	18.07	0.344

Healthcare utilisation	24.44	22.07	0.415

	No Bone Graft(n = 18)	Bone Graft(n = 29)	p value

Psychological distress	19.14	38.37	0.024

Physical symptoms other than neck/arm pain	12.96	18.07	0.344

Healthcare utilisation	24.44	22.07	0.415


Step	(min) Time	(W) Power	Temp. (°C)

4	15	350	195


Locality	Taxon	Site	Latitude	Longitude	Depth (m)	No. of tube fragments*

Antarctic	Sclerolinum sp.	Hook Ridge Site 1	−62.1969	−57.2975	1174	686*

		Hook Ridge Site 2	−62.1924	−57.2783	1054	87*

		Kemp Caldera	−59.6948	−28.35	1432	95*

Arctic	S. contortum	Loki’s Castle CG2009	73.5662	8.1585	2357	33*

		Loki’s Castle CG2008	73.5662–73.5683	8.1585–8.1563	-	8*

		HMMV CG2010	71.9975–71.9999	14.7329–14.7316	1262	1*

		HMMV VICKING 2006	72.0013	14.7225	1270	50+

GoM	S. contortum	Walker Ridge WR269	26.6833	−91.65	1954	21*

Locality	Taxon	Site	Latitude	Longitude	Depth (m)	No. of tube fragments*

Arctic	S. contortum	Loki’s Castle CG2009	73.5662	8.1585	2357	33*

		Loki’s Castle CG2008	73.5662–73.5683	8.1585–8.1563	-	8*

		HMMV CG2010	71.9975–71.9999	14.7329–14.7316	1262	1*

		HMMV VICKING 2006	72.0013	14.7225	1270	50+

GoM	S. contortum	Walker Ridge WR269	26.6833	−91.65	1954	21*


Data source	# of annotated exons	# of mapped exon


		Recalling and understanding (part A)	Applying (part B)	Total (part A & B)

N	M	SD	Min–max	M	SD	Min–max	M	SD	Min–max

Pre-test	7	3.07	1.26	1–5	0.86	0.69	0–2	3.93	1.16	3–6

Post-test	7	5.07	1.15	4–7	1.57	0.98	0–3	6.64	1.27	5–9

Follow-up	7	5.14	1.56	4–8	1.29	0.95	0–3	6.43	2.16	5–11

		Recalling and understanding (part A)	Applying (part B)	Total (part A & B)

N	M	SD	Min–max	M	SD	Min–max	M	SD

Pre-test	7	3.07	1.26	1–5	0.86	0.69	0–2	3.93	1.16

Post-test	7	5.07	1.15	4–7	1.57	0.98	0–3	6.64	1.27

Follow-up	7	5.14	1.56	4–8	1.29	0.95	0–3	6.43	2.16

Total (part A & B)

Min–max

3–6

5–9

5–11


Farm	1	2	3	4	5	6	7	8

yers on the farm	o	Yes		s	Yes	Yes	es

nr. of layers on the farm	0*	6,000	12,000	15,000	20,000	18,000	16,000	0

Salmonella PCR	+	+	-	-	-	-	-	+


	Percentage agree or strongly agree (n = 37)

Knowledge translation was hampered by a lack of incentives for KTE activities within organisations that conduct health systems and policy research (HSPR)	38

Organisations that conduct HSPR made available financial and human resources to assist with KTE activities	24

Organisations that conduct HSPR were not seen as a credible source of research	14


 	 	ID code	Sex	Age (Years)	Time in facility (Years)	Staff position

Dyads

 	Dyad 1

 	 	Resident	R1	F	84	6

 	 	Family	F1	F	55

 	Dyad 2

 	 	Resident	R2	F	79	1.5

 	 	Family	F2	F	56

 	Dyad 3

 	 	Resident	R3	M	89	1

 	 	Family	F3	F	43

 	Dyad 4

 	 	Resident	R4	F	84	2

 	 	Family	F4	M	53

 	Dyad 5

 	 	Resident	R5	F	89	3

 	 	Family	F5(a)	F	57

 	 	Family	F5(b)	M	62

Staff

 	Staff 1	S1	F	54	 	Lifestyle manager

 	Staff 2	S2	F	41	 	Personal Care Worker

 	Staff 3	S3	F	50	 	Care Manager

 	Staff 4	S4	F	-	 	Personal Care Worker

 	Staff 5	S5	F	60	 	Enrolled Nurse

 	Staff 6	S6	F	52	 	Diversional Therapist

 	Staff 7	S7	F	30	 	Endorsed Enrolled Nurse

		ID code	Sex	Age (Years)	Time in facility (Years)	Staff position

		Resident	R3	M	89	1

		Family	F3	F	43

	Dyad 4

		Resident	R4	F	84	2

		Family	F4	M	53

	Dyad 5

		Resident	R5	F	89	3

		Family	F5(a)	F	57

		Family	F5(b)	M	62

Staff

	Staff 1	S1	F	54		Lifestyle manager

	Staff 2	S2	F	41		Personal Care Worker

	Staff 3	S3	F	50		Care Manager

	Staff 4	S4	F	-		Personal Care Worker

	Staff 5	S5	F	60		Enrolled Nurse

	Staff 6	S6	F	52		Diversional Therapist

	Staff 7	S7	F	30		Endorsed Enrolled Nurse


Mitochondrial abnormality	MS	CFS	PD	AUT	MDD	Schiz	BPD

Ultrastructural abnormalities in mitochondria	+	++	+	+	+	+++	+

Evidence to shift in energy production via glycolysis	+	++	++	++		++	++

Mitochondrial dysfunction in peripheral immune cells	+	++	++	++	++	++	+

Mitochondria DNA damage	+					++

Damage to the electron transport chain	++		+++	+		++	+

High lactate in brain or cerebrospinal fluid	+	+	+	+	+	++	+

Bioenergetic impairment Skeletal muscle		+++			+

Decreased mitochondrial membrane potential		+	+


	Age/Gender	Experience in Using EPW	Type of Disabilities

Motor	Cognition

User I	60-year-old male	Yes	Lower body amputation by diabetes	Low cognition/reflexes by dementia

User II	48-year-old female	Yes	Amyotrophic lateral sclerosis	-

User III	32-year-old female	Yes	Cerebral palsy	-

User IV	73-year-old male	Yes	Lack of strength	Weak senile dementia

User V	28-year-old female	Yes	Spinal cord injury	-

	Age/Gender	Experience in Using EPW	Type of Disabilities

Motor	Cognition

User V	28-year-old female	Yes	Spinal cord injury	-


Group	EPG	Egg reduction rate (%)

PBS (n = 5)	76.60 ± 7.427	–

B.s-CotC (n	74.80 ± 8	–


 Diagnosis	12 to 14 years old	15 to 17 years old

(n = 9)	(n = 7)

ADHD	3	1

ODD		2

MDD		2

PTSD	1

Social phobia	1

ADHD/DBD	2

ADHD/ODD	1

ADHD/MDD		2

ADHD/PTSD/ODD	1

Diagnosis	12 to 14 years old	15 to 17 years old

(n = 9)	(n = 7)

ADHD/MDD		2

ADHD/PTSD/ODD	1


Genus/subgenus	Species	No. of unique conotoxin precursors	No. of unique mature toxins	No. of gene superfamilies	No. of cysteine frameworks	Most abundant gene superfamily and frequencya	Main diet summarized from [29, 42]

Puncticulis	arenatus	326	256	36	31	O1, (20.3 %)	eunicids, nereids, capitellids

Californiconus	californicus	185	164	30	21	O1, (20.1 %)	molluscs, polychaetes, fish

Virroconus	coronatus	331	286	32	30	O1, (19.6 %)	eunicids, capitellids

Virroconus	ebraeus	75	69	27	23	M, (31.9 %)	eunicids, nereids

Stephanoconus	imperialis	70	66	20	19	P, (16.7 %)	amphinomids

Lividoconus	lividus	244	204	31	25	O1, (10.7 %)	enteropneusts, terebellids

Conus	marmoreus	81	69	14	16	M, (26.1 %)	gastropods

Lividoconus	quercinus	97	78	25	23	O1, (15.4 %)	enteropneusts, sabellids

Rhizoconus	rattus	102	89	28	30	con-ikot-ikot, (18 %)	eunicids

Harmoniconus	sponsalis	401	338	35	29	O1, (28.1 %)	eunicids, nereids

Strategoconus	varius	198	168	29	24	M, (10.7 %)	polychaetes

Virgiconus	Virgo	113	78	25	21	O1, (24.4 %)	terebellids

Genus/subgenus	Species	No. of unique conotoxin precursors	No. of unique mature toxins	No. of gene superfamilies	No. of cysteine frameworks	Most abundant gene superfamily and frequencya	Main diet summarized from [29, 42]

Virroconus	coronatus	331	286	32	30	O1, (19.6 %)	eunicids, capitellids

Virroconus	ebraeus	75	69	27	23	M, (31.9 %)	eunicids, nereids

Stephanoconus	imperialis	70	66	20	19	P, (16.7 %)	amphinomids

Lividoconus	lividus	244	204	31	25	O1, (10.7 %)	enteropneusts, terebellids

Conus	marmoreus	81	69	14	16	M, (26.1 %)	gastropods

Lividoconus	quercinus	97	78	25	23	O1, (15.4 %)	enteropneusts, sabellids

Rhizoconus	rattus	102	89	28	30	con-ikot-ikot, (18 %)	eunicids

Harmoniconus	sponsalis	401	338	35	29	O1, (28.1 %)	eunicids, nereids

Strategoconus	varius	198	168	29	24	M, (10.7 %)	polychaetes

Virgiconus	Virgo	113	78	25	21	O1, (24.4 %)	terebellids


	Customers-Suppliers vignettes	Employees-Suppliers vignettes	Employees-Environment vignettes

	Effect	SE	LL95%CI	UL95%CI	Effect	SE	LL95%CI	UL95%CI	Effect	SE	LL95%CI	UL95%CI

−1	0.20	0.09	0.0	0	0.		−0	0.63	−0.2	0.	−0	−


Symptoms	EG	YG	P

Heartburn	1.6 ± 0.89	2.8 ± 0.76	<0.05

Acid regurgitation	1.6 ± 0.98	2.4 ± 0.91	<0.05

Solid food dysphagia	1.7 ± 0.78	0.6 ± 0.22	<0.05

Chest pain	1.7 ± 0.84	1.5 ± 0.89	>0.05

Respiratory complication	1.9 ± 1.06	1.1 ± 0.47	<0.05

id regurgitation	6 ± 0.98		05

Solid food dysphagia	1.7 ± 0.78	0.6 ± 0.22	<0.05

Chest pain	1.7 ± 0.84	1.5 ± 0.89	>0.05

Respiratory complication	1.9 ± 1.06	1.1 ± 0.47	<0.05


Norm Method	% Correct	Sensitivity	Specificity	Between-mean array correlation (after normalization)	Between array coefficient of variation (after normalization)	Confounding index (after normalization)

SGM-Cond Log Trans	0.36	1	0.202	0.966	0.886	1.026

Quantile 50	0.36	0.941	0.217	0.622	2.417	0.989

Trimmed Mean 25–75	0.36	0.941	0.217	0.768	1.915	0.989

Median	0.348	0.941	0.202	0.694	2.2	0.989


	Cases	Deaths

Cervical cancer	1344	492

CIN2+	4528	–

CIN1	2532	–

Vaginal cancer	14	4

Vulvar cancer	20	6

Anal cancer females	242	75

Anal cancer males	79	34

Genital warts females	33,091	–

Genital warts males	24,258	–

Total	66,108	611

	Cases	Deaths

Cervical cancer	1344	492

CIN2+	4528	–

CIN1	2532	–

Vaginal cancer	14	4

Vulvar		6

 cancer	20

Anal cancer females	242	75

Anal cancer males	79	34

Genital warts females	33,091	–

Genital warts males	24,258	–

Total	66,108	611


Antimicrobial agents	Breakpoint for resistance (mg/L)	% Resistant	Range (mg/L)	MIC50 (mg/L)	MIC90 (mg/L)

Imipenem	≥8	100	8–128	32	64

Meropenem	≥8	99	4–128	32	64

Amikacin	≥64	87	0.5 – > 512	>512	>512

Ciprofloxacin	≥4	100	32 – > 512	>512	>512

Colistin	≥4	5	0.125–16	0.5	1

Tigecycline	-	-	≤0.125–16	1	8


	Cohorta	Claimantsb

	Odd Ratio*	95 % Confidence Interval	Odd Ratio*	95 % Confidence Interval

Top cost percentile during 2010

Top 1 Percentile	0.99	0.84	1.15	1.66c	1.42	1.94

Top 5 Percentile	0.8c	0.74	0.85	1.34c	1.25	1.43

Incremental Effect on PMPY	-$323.08	-$345.54	-$278.07	$494.72	$461.63	$526.01

	Cohorta	Claimantsb

	Odd Ratio*	95 % Confidence Interval	Odd Ratio*	95 % Confidence Interval

Top cost percentile during 2011

Top 1 Percentile	1.17c	1.01	1.37	1.80c	1.55	2.10

Top 5 Percentile	0.96	0.89	1.02	1.47c	1.37	1.57

Incremental Effect on PMPY	-$88.22	-$133.59	-$42.84	$831.80	$763.38	$879.21

Top cost percentile during 2010 and 2011 combined

Top 1 Percentile	1.11	0.97	1.27	1.60c	1.40	1.84

Top 5 Percentile	0.89c	0.84	0.95	1.29c	1.25	1.41

Incremental Effect on PMPY	-$411.44	-$491.53	-$348.55	$647.10	$570.87	$703.56


Mean of self-monitored FPG values from preceding 3 days	Adjust of nocturnal basal insulin dosage (IU/day)

<90 mg/dL (5.0 mmol/L)	−1

90-130 mg/dL (5.0-7.2 mmol/L)	No adjustment

>130 mg/dL (7.2 mmol/L)	+2

Mean of self-monitored pre-dinner values from preceding 3 days	Adjust of diurnal basal insulin dosage (IU/day)

<90 mg/dL (5.0 mmol/L)	−2

90-130 mg/dL (5.0-7.2 mmol/L)	No adjustment

>130 mg/dL (7.2 mmol/L)	+2

Mean of self-monitored postprandial values from preceding 3 days	Adjust of prandial insulin dosage (IU/day)

<90 mg/dL (5.0 mmol/L)	−1

90-180 mg/dL (5.0-10.0 mmol/L)	No adjustment

>180 mg/dL (10.0 mmol/L)	+1


EV71 vaccine candidates	Adjuvant formulated

VP1-43	Alum

VP1-43	CFA/IFA

VP2-28	Alum

VP2-28	CFA/IFA

VP1-43/VP2-28	CFA/IFA

rVP1	Alum

rVP1	CFA/IFA

rVP2	Alum

rVP2	CFA/IFA

rVP3	Alum

rVP3	CFA/IFA

EV71-VLP	PBS

EV71-VLP	Alum

EV71-VLP	CFA/IFA

2 μg of inactivated

EV71 virion	PBS

EV71 virion	Alum

5 μg of inactivated

EV71 virion	Alum


System	Prosthetic crown

8 mm	13 mm

Neodent	31.43 ±15.44Aa	28.13 ± 12.66Aa

Bicon	26.18 ± 13.00Ba	30.92 ± 14.89Aa


	Number of patients (percentage of sample in parentheses)

Age

<=60 years	1743 (65.1%)

>60 years	936 (34.9%)

Gender

Female	1439 (53.7%)

Male	1240 (46.3%)

Body mass index

<=25 kg/m2	309 (11.5%)

>25 to < =30 kg/m2	1003 (37.4%)

= > 30 kg/m2	1367 (51.0%)

Smoking status

Current smoker	464 (17.3%)

Ex-smoker	301 (11.2%)

Non-smoker	1914 (71.4%)

Country

Eastern European countries	1763 (65.8%)

Western-central European countries	916 (34.2%)


	Intrathecal morphine (n = 50)	Epidural analgesia (n = 50)	P

Patients with complications	8 (16%)	11 (22%)	.59

 Biloma	1 (2%)	1 (2%)	.89

 Hepatic insufficiency	2 (4%)	3 (6%)	.88

 Wound infection	3 (6%)	4 (8%)	.73

 Pleural effusion	1 (2%)	2 (4%)	.78

 Pneumonia	—	1 (2%)	—

 Urinary tract infection	1 (2%)	—	—

	Intrathecal morphine (n = 50)	Epidural analgesia (n = 50)	P

Hepatic insufficiency	2 (4%)	3 (6%)	.88

Wound infection	3 (6%)	4 (8%)	.73

Pleural effusion	1 (2%)	2 (4%)	.78

Pneumonia	—	1 (2%)	—

Urinary tract infection	1 (2%)	—	—


Molar ratio	Vitamin K recovery (%)	Lipid recovery (%)	Loading capacity (w %)	Size (nm)

0.22	98.4 ± 2.8	96.3 ± 0.4	5.0 ± 0.2	11.0 ± 1.4

Molar ratio	Vitamin K recovery (%)	Lipid recovery (%)	Loading capacity (w %)	Size (nm)

0.44	91.3 ± 2.0	89.5 ± 4.1	9.9 ± 0.2	19 ± 6

0.88	42.6 ± 1.5	41.1 ± 3.9	18.4 ± 0.5	44 ± 5


Results of TST	Results of T.SPOT.TB

Negative	Positive	Indeterminate	Total

Negative	79	3	4	86

Positive	4	2	0	6

Total	83	5	4	92

Results of TST	Results of T.SPOT.TB

Negative	Positive	Indeterminate	Total

Negative	79	3	4	86

Positi	4


Criteria/Quantitative description	Score

Background blood/clot

Large amount; great compromise in diagnosis	0

Moderate amount; diagnosis possible	1

Minimal; diagnosis	2

Amount of cellular material

Minimal to absent; diagnosis not possible	0

Sufficient for diagnosis	1

Abundant; diagnosis possible	2

Degree of cellular degeneration

Degeneration marked; diagnosis impossible	0

Degeneration moderate; diagnosis possible	1

Degeneration minimal; diagnosis obvious	2

Degree of cellular trauma

Marked; diagnosis impossible	0

Moderate; diagnosis possible	1

Minimal; diagnosis obvious	2

Retention of appropriate architecture

Minimal to absent; non-diagnostic	0

Moderate; some preservation of, e.g., follicle, papillae, acini, etc.	1

Excellent architectural display closely reflecting histology; diagnosis obvious	2


	Strains with Stable ST

Patient	ST of the first CoS strain isolated	Sample type	Sample type of first clinical CoS	ST of CoR strain isolated	Sample type	Time to switch from CoR to CoS (days)

1	554	SRS	Arterial catheter	-	bronchial aspirate	36

2	512	SRS	skin swab	-	urine	26

3	307	SRS	skin swab	-	skin swab	42

4	512	SRS	skin swab	-	SRS	123

5	512	SRS	drainage fluid	-	drainage fluid	28

6	512	urine	urine	-	urine	17

7	512	SRS	bronchial aspirate	-	SRS	74

8	1543	SRS	-	-	SRS	50

9	512	SRS	bronchial aspirate	-	bronchial aspirate	31

10	512	SRS	bronchial aspirate	-	bronchial aspirate	6

11	554	SRS	-	-	bronchial aspirate	na

12	512	SRS	bronchial aspirate	-	blood	24

13	258	SRS	urine	-	urine	8

						Median

29.5 days

	Switched ST

Patient	ST of the first CoS strain isolated	Sample type	Sample type of first clinical CoS	ST of CoR strain isolated	Sample type	Time to switch from CoR to CoS (days)

14	15	SRS	urine	512	SRS	167

15	554	urine	urine	512	SRS	67

16	2581	SRS	skin swab	512	SRS	34

17	554	SRS	arterial catheter	1733 (554 SLV)	drainage fluid	54

						Median:

60.5 days


	Word-pairs	Sentences	Oddball	Mean per task

Ignore task	M	32.55	55.99	46.89	45.15

	SD	22.08	56.99	40.52	42.66

Passive task	M	72.91	80.01	89.39	80.77


Area	WT TA (o)	SOD TA (o)	WT TA (i)	SOD TA (i)	WT Soleus	SOD Soleus

Junctional fold diameter (nm)	65.24 ± 2.90	67.60 ± 2.88	72.014 ± 4.46	65.26 ± 4.27	79.06 ± 4.43	73.02 ± 4.30


Cost in CDN dollars Mean (SD)

Total Cost	$49,923 (45,773)

Total Indirect Cost	$13,566 (12,625)

Total Direct Cost	$36,358 (33,501)

Direct Costs per costing Category

 Health Professionals	$2600 (4787)

 Imaging	$1069 (1428)

 Lab	$1923 (1709)

 Nursing	$16,378 (16,735)

 Operating room	$1192 (1819)

 Surgical Implants	$907 (2821)

 Post anaesthesia care unit	$307 (590)

 Pharmacy	$3273 (4157)

 Special Care Unit	$7502 (16,929)

 Endoscopy	$72 (223)

 Food Services	$1134 (1247)


Factor	Univariable HR	p-value	Multivariable HR (95% CI)	p-value

Monitoring randomisation

LCM	1.00	-	1.00	-

CDM	1.07	0.45	1.11 (0.93 - 1.35)	0.25

Gender

Male	1.00	-	1.00	-

Female	0.80	0.02	0.79 (0.65 - 0.95)	0.01

Initial ART


Method	Planar objects	Real feet	Main disadvantages

 	Accuracy/Repeatibility	Static/Dynamic

Coudert et al.[13]	NA/NA	NA/NA	Technique requires spraying foot with paint or adding sock

Jezersek & Mazina [14]	0.2 mm/NA	0.4 mm/NA	The system requires several specialized camera-projector-mirror systems

Jezersek et al.[16]	0.5 mm/NA	NA/NA	Similar to Jezersek & Mazina, the system requires expensive specialized equipment

Kouchi et al.[17]	0.5 mm/NA	2.0 mm/NA	System only measures 4 cross-section areas of the foot, which need to be manually marked on the foot surface

Schmeltzpfenning et al.[18]	NA/NA	NA/NA	Camera-projector systems work sequentially thus reducing the acquisition frequency

Mochimaru et al.[20]	NA/NA	NA/NA	Matching random pattern is computationally expensive and can create unpredictable errors

Yoshida & Kouchi [21]	NA/NA	4.0 mm/NA	System uses one generic model for all foot reconstructions; shape deformations during walking cannot be fully accounted by the generic model

Liu et al.[22]	0.25 mm/NA	NA/NA	System provides good visual results, but lacks proper experiments with real feet

Blenkinsopp et al.[25]	NA/NA	NA/NA	Reconstruction is based on painted artifacts on the foot surface


Response to endotoxin administration	Clinical	Autonomic	Immune

Outcome expectancies	Flu-like symptoms (T90)	Epinephrine (T0)	IL-10 (T60)	TNF-α (T90)	IL-6 (T120)	IL-8 (T120)

Generalized outcome expectancies

Optimism (LOT-R)	−.38	.76**	.60*	−.32	−.26	−.32

Neuroticism (BFI)	.10	−.32	−.09	.27	.22	.11

Specific outcome expectancies	−.71**	.28	.33	.00	.16	−.15

Response to endotoxin administration	Clinical	Autonomic	Immune

Outcome expectancies	Flu-like symptoms (T90)	Epinephrine (T0)	IL-10 (T60)	TNF-α (T90)	IL-6 (T120)	IL-8 (T120)

Optimism (LOT-R)	−.38	.76**	.60*	−.32	−.26	−.32

Neuroticism (BFI)	.10	−.32	−.09	.27	.22	.11

Specific outcome expectancies	−.71**	.28	.33	.00	.16	−.15


Surfactant	Drug loaded	Comments	References

Brij 35, 78, 98, and 700	Atenolol, timolol, betaxololcyclosporine A	Significantly increased the corneal permeability.Significantly increased bioavailability of ophthalmic drugs by using contact lenses.	[52, 76]

Polysorbate 80, polyoxyl 40 stearate, and polyoxyl 60 hydrogenated castor oil	Cyclosporine A	Improve ocular CsA penetration and are clinically useful in the treatment of immune-mediated ophthalmic diseases.	[71]

Pluronic F127	Pilocarpine	Enhanced miotic response to a single instillation of pilocarpine eye drops compared to an aqueous solution of the drug.	[68]

Polysorbates 60 and 80 and Brij 35	Gentamicin sulphate	Effective in the prolongation of drug release from the ocular delivery and observed no irritancy on albino rabbits.	[72]

Polysorbate 20	Cyclopentolate	Promoted ocular absorption.	[23, 25]

Solulan C-24 and span 60	Timolol maleate	Treatment of ocular hypotensive activity. Exhibited sustained controlled ocular drug delivery.	[45, 46]

Spans 20, 40, 60, and 80	Acyclovir	Effective for the treatment of herpes simplex keratitis.	[67]

Acetazolamide	Effective in enhancing the bioavailability of drug and lowered the intraocular pressure.	[43, 45, 73]

Brimonidine tartrate	Improved bioavailability and increased precorneal residence time.Decreased the intraocular pressure for a prolonged period of time and nonirritant effect	[77–80]

Naltrexone hydrochloride	Possessed better ocular tolerability and less ocular irritation.	[74]

Fluconazole	Improved permeability as compared to marketed formulation and nonirritant effect.	[25]

Flupirtine maleate	Improved the low corneal permeability for effective management of trigeminal neuralgia.	[75]

Diclofenac sodium	Nonirritant and safe vesicular system for the effective ocular drug delivery.	[68]

Levofloxacin.	Efficient in prolonging the drug release with reduced side effects.	[69]

Surfactant	Drug loaded	Comments

Brij 35, 78, 98, and 700	Atenolol, timolol, betaxololcyclosporine A	Significantly increased the corneal permeability.Significantly increased bioavailability of ophthalmic drugs by using contact lenses.

Polysorbate 80, polyoxyl 40 stearate, and polyoxyl 60 hydrogenated castor oil	Cyclosporine A	Improve ocular CsA penetration and are clinically useful in the treatment of immune-mediated ophthalmic diseases.

Pluronic F127	Pilocarpine	Enhanced miotic response to a single instillation of pilocarpine eye drops compared to an aqueous solution of the drug.

Polysorbates 60 and 80 and Brij 35	Gentamicin sulphate	Effective in the prolongation of drug release from the ocular delivery and observed no irritancy on albino rabbits.

Polysorbate 20	Cyclopentolate	Promoted ocular absorption.

Solulan C-24 and span 60	Timolol maleate	Treatment of ocular hypotensive activity. Exhibited sustained controlled ocular drug delivery.

Spans 20, 40, 60, and 80	Acyclovir	Effective for the treatment of herpes simplex keratitis.

Acetazolamide	Effective in enhancing the bioavailability of drug and lowered the intraocular pressure.

Brimonidine tartrate	Improved bioavailability and increased precorneal residence time.Decreased the intraocular pressure for a prolonged period of time and nonirritant effect

Naltrexone hydrochloride	Possessed better ocular tolerability and less ocular irritation.

Fluconazole	Improved permeability as compared to marketed formulation and nonirritant effect.

Flupirtine maleate	Improved the low corneal permeability for effective management of trigeminal neuralgia.

Diclofenac sodium	Nonirritant and safe vesicular system for the effective ocular drug delivery.

Levofloxacin.	Efficient in prolonging the drug release with reduced side effects.


	Intention to quit	Quitting smoking

	OR	95 % CI	OR	95 % CI

Province (Hanoi vs Nam Dinh)	0.47***	0.34	0.67	0.50*	0.23	1.08

Location (Urban vs Rural)	1.44	0.90	2.31

Duration of MMT (month)	1.00	0.99	1.02	0.99	0.95	1.03

Outpatient service use last 12 months (yes vs no)	1.98***	1.44	2.72

# of drug rehabilitation				1.03	0.98	1.07

Religion (vs cult of ancestors)

 Buddhism				2.72*	0.84	8.78

Occupation (vs unemployed)

 Other jobs	1.41	0.87	2.28

Age (vs 18–<25)

 35–<40				2.63**	1.30	5.30

 ≥45	0.51***	0.34	0.78

Marital status (vs single)

 Live with spouse	1.23	0.91	1.67

Income quintile (vs poorest)

 Rich	0.78	0.56	1.09

Having pain/discomfort (yes vs no)				0.41	0.12	1.43

HIV status (vs negative)

 Positive	0.58**	0.34	0.99

Body mass index (vs underweight)

 Normal	1.47	0.86	2.52

Level of nicotine dependence (vs very low)

 Low				0.31**	0.12	0.81

 Moderate				0.22**	0.05	0.97

 High				0.37**	0.13	1.04

 Very high				0.22**	0.05	0.99

Year of smoking				0.95**	0.91	1.00

	Intention to quit

	OR	95 % CI

Province (Hanoi vs Nam Dinh)	0.47***	0.34

Location (Urban vs Rural)	1.44	0.90

Duration of MMT (month)	1.00	0.99

Outpatient service use last 12 months (yes vs no)	1.98***	1.44

# of drug rehabilitation

Religion (vs cult of ancestors)

Buddhism

Occupation (vs unemployed)

Other jobs	1.41	0.87

Age (vs 18–<25)

35–<40

≥45	0.51***	0.34

Marital status (vs single)

Live with spouse	1.23	0.91

Income quintile (vs poorest)

Rich	0.78	0.56

Having pain/discomfort (yes vs no)

HIV status (vs negative)

Positive	0.58**	0.34

Body mass index (vs underweight)

Normal	1.47	0.86

Level of nicotine dependence (vs very low)

Low

Moderate

High

Very high

Year of smoking


Fat mass, kg

Week 0–10

Week 0–56

Fat mass, %

Week 0–10

Week 0–56

Lean mass, kg

Week 0–10

Week 0–56

VAT area, mm2

Week 0–10

Week 0–56

Body weight, kg

Week 0–10

Week 0–56


Documentation practice	Description	Number of sites

Paper-based documentation	Documentation on a structured paper-based template and later scanned into the EHR in pdf format. No entries of vital signs were done in the EHR.	2 Sites

Mixed Documentation	Done on a paper-based template and later transferred into a digital EHR template.	3 sites

Digital documentation	Documentation on a digital template	4 sites

Documentation practice	Description	Number of sites

Digital documentation	Documentation on a digital template	4 sites


Variable	Number	% of total	% male	% female

	Unknown	5,595	8.7	8.6	9.0

Country of birth

	Israel	50,726	79.0	78.4	80.1

	Asia, Africa	1,298	2.0	2.4	1.5

	West	1,861	2.9	3.1	2.6

	Former Soviet Union	6,776	10.6	10.8	10.1

	Unknown	3,518	5.5	5.3	5.8


Study	Patients (#)	SRS median total dose/fx	Follow-up median, range (months)	Tumor size median, range (cc)	Prior irradiation Dose, median, range (Gy)	Toxicity	Complete Response Rate	Overall survival

Voynov et al. [13]	22	24/1-8	19, 11-40*	19.1, 2.5-140.3	97.8, 70.1-190.3 (BED10)	No Grade 4+	-	22% at 2-yrs

			N	4	66-69	No Gr	8.6	18% at


HospitalVolume	No. ofhospitals inJapan	No. of beds in Japan (Ni)	No. of beds in DPCparticipating hospitals (ni)	No. of intussusceptionfrom July to December(Xi)	Estimated No. of cases per year(Yi)

Total	7,723	910,238	341,625	309,465	457	415	1,957 (1743-2216)	2,081 (1802-2361)


Materials	Melting	Solidification

Onset temperature (°C)	End temperature (°C)	Enthalpy (J/g)	Onset temperature (°C)	End temperature (°C)	Enthalpy (J/g)

FS TD-MA PCM	0 cycling	33.15	37.75	128.60	30.72	27.63	125.70

500 cycling	32.81	37.28	125.30	31.11	28.00	123.40

1000 cycling	32.65	37.04	123.50	31.72	28.55	121.70


 	 Total	 Woman	 Man

Total thyroidectomy	 166	 125 (75.3)∗	 41 (24.7)

Pyramidal lobe present	 109 (65.7)	 82 (65.6)	 27 (65.9)

Pyramidal lobe absent	 57 (34.3)	 43 (34.4)	 14 (34.1)


Parameters	Control group	500 mg/kg·b·wt (A)	1000 mg/kg·b·wt (B)	2000 mg/kg·b·wt (C)

Number of examined fetuses	15	15	15	15

Impairment of skull ossification	—	3 (20%)	5 (33.33%)	8 (53.33%)

Absence or dislocation of sternebrae	—	2 (13.33%)	3 (20%)	5 (33.33%)

Reduction or absence of caudal vertebrae	—	5 (33.33%)	6 (40%)	10 (66.67%)

Absence of digit's bone of fore limb	—	3 (20%)	4 (26.67%)	9 (60%)

Absence of digit's bone of hind limb	—	2 (12.33%)	3 (20%)	7 (46.67%)

Absence of some metatarsal bone	—	3 (20%)	4 (26.67%)	6 (40%)

Absence of some metacarpal bone	—	2 (12.33%)	4 (26.67%)	5 (33.33%)

Parameters	Control group	500 mg/kg·b·wt (A)	1000 mg/kg·b·wt (B)	2000 mg/kg·b·wt (C)

Absence or dislocation of sternebrae	—	2 (13.33%)	3 (20%)	5 (33.33%)

Reduction or absence of caudal vertebrae	—	5 (33.33%)	6 (40%)	10 (66.67%)

Absence of digit's bone of fore limb	—	3 (20%)	4 (26.67%)	9 (60%)

Absence of digit's bone of hind limb	—	2 (12.33%)	3 (20%)	7 (46.67%)

Absence of some metatarsal bone	—	3 (20%)	4 (26.67%)	6 (40%)

Absence of some metacarpal bone	—	2 (12.33%)	4 (26.67%)	5 (33.33%)


Criteria	Total n	Normosmic	Hyposmic	Anosmic

TOAST criteria

 Large artery atherosclerosis	11	7	2	2

 Cardioembolism	21	14	4	3

 Small vessel occlusion	14	7	4	3

 Stroke of other determined etiology	1	1	0	0

 Stroke of undetermined etiology	26	11	11	4

OCPS criteria

 PACI	37	18	11	8

 POCI	12	9	2	1

 TACI	4	2	1	1

 LACI	20	11	7	2


Variable	Response	Surgeon 1	Surgeon 2	P

Operative time, no previous abdominal surgery	N, Mean ± SD	59, 45.6 ± 12.9	13, 73.2 ± 13.6	< 0.001

Operative time, previous abdominal surgery	N, Mean ± SD	43, 44.0 ± 12.6	2, 115.5 ± 2.1	0.019

Variable	Response	Surgeon 1	Surgeon 2	P

Operative time, previous abdominal surgery	N, Mean ± SD	43, 44.0 ± 12.6	2, 115.5 ± 2.1	0.019


	"0" + EC	"0" + NEC	p

Number of cycles	50	39

Maternal age (mean ± SD)	30.3 ± 4.0	31.6 ± 3.4	>0.5

Total number of embryos transferred	75	75

Mean ± SD embryos/cycle	1.5 ± 0.5	1.9 ± 0.5	0.000

Biochemical pregnancies	30	17

bPR (%)	60	44	>0.5

Clinical pregnancies	28	12

cPR (%)	56	31	0.020

Number of gestational sacs by US	32	20

IR (%)	43	27	0.038


Age, sex	NOAC	Lesion	Prescription (month)	BARC	Other factors

Upper GI

 92 F	D	Gastric ulcer	11	3a	PPI (-)

 96 F	R	Gastric ulcer	42	3a	PPI (-)

 63 M	R	Duodenal ulcer	29	3b	PPI (-)

 74 M	R	Gastric ulcer	32	3a	PPI (-)

 83 F	A	Gastric ulcer	16	3a	PPI (-)

 84 M	A	Ulcers/o	12	3a	PPI (-), steroid

 72 M	A	Duodenal ulcer	25	3b	PPI (-), operation

Lower GI

 78 M	D	Ileal erosion	23	3a	DAPT

 80 M	D	Colon diverticulosis	7	3a	-

 72 F	R	Colon vascular ectasia	8	3a	NSAID, steroid

 75 M	R	Post EMR for colon polyp	24	3a	LDA

 85 F	A	Colon diverticulosis	3	3b	NSAID

Age, sex	NOAC	Lesion	Prescription (month)	BARC	Other factors

72 M	A	Duodenal ulcer	25	3b	PPI (-), operation

Lower GI

78 M	D	Ileal erosion	23	3a	DAPT

80 M	D	Colon diverticulosis	7	3a	-

72 F	R	Colon vascular ectasia	8	3a	NSAID, steroid

75 M	R	Post EMR for colon polyp	24	3a	LDA

85 F	A	Colon diverticulosis	3	3b	NSAID


New

Risk Factor		Adjusted Odds Ratio	95% Confidence Interval	P-value

Any family member suffering from hepatitis B & C	Yes	14.5	9.5-22.1	0.001

	No	Reference

Dental extract/filling/scaling	Yes	1.9	1.4-2.7	0.001

	No	Reference

Blood transfusion	Yes	2.9	1.2-7.3	0.017

	No	Reference

History of IV/IM injection/year	None	Reference

	< 5/year	2.1	1.3-3.4	0.003

	≥/year	5.8	3.5-9.6	0.001

New

Blood transfusion	Yes	2.9	1.2-7.3	0.017

	No	Reference

History of IV/IM injection/year	None	Reference

	< 5/year	2.1	1.3-3.4	0.003

	≥/year	5.8	3.5-9.6	0.001


Case	Age	Gender	HSCT source	Underlying disease	Interval between HSCT and CM analysis (mo)	Interval between DE onset and CM analysis (mo)	Interval between HSCT and DE onset (mo)	DE severity level	CC	Clinically affected cGVHD organs

1	57	Male	PBSC	ML	17	1	16	3	-	Eye, Skin

2	47	Male	PBSC	AML	19	6	13	4	+	Eye, Skin, Mouth, Liver

3	50	Male	PBSC	MM	12	1	11	4	+	Eye, Mouth

4	47	Female	BM	MM	43	1	42	4	+	Eye, Mouth

5	38	Female	BM	AML	12	0	12	2	-	Eye

6	57	Male	BM	MDS	14	N.A.	N.A.	3	+	Eye

7	51	Male	BM	CML	120	48	72	2	-	Eye

8	46	Female	PBSC	MM	116	108	8	2	-	Eye

9	55	Male	PBSC	AML	25	17	8	4	+	Eye, Skin

Case	Age	Gender	HSCT source	Underlying disease	Interval between HSCT and CM analysis (mo)	Interval between DE onset and CM analysis (mo)	Interval between HSCT and DE onset (mo)	DE severity level	CC	Clinically affected cGVHD organs

1	57	Male	PBSC	ML	17	1	16	3	-	Eye, Skin

2	47	Male	PBSC	AML	19	6	13	4	+	Eye, Skin, Mouth, Liver

3	50	Male	PBSC	MM	12	1	11	4	+	Eye, Mouth

4	47	Female	BM	MM	43	1	42	4	+	Eye, Mouth

5	38		BM	AM	1	0	1		-	Eye

		Female		L	2		2	2

6	57	Male	BM	MDS	14	N.A.	N.A.	3	+	Eye

7	51	Male	BM	CML	120	48	72	2	-	Eye

8	46	Female	PBSC	MM	116	108	8	2	-	Eye

9	55	Male	PBSC	AML	25	17	8	4	+	Eye, Skin


SNP rsID	Marker name	Amino acid change	Chromosome	Cytoband	P-values

rs4149015	SLCO1B1 c.-11187G > A	Promoter	12	p12.2	0.0001

rs1060253	SLC7A5 c.∗438C > G	3′UTR	16	q24.2	0.0005


 	Active partitions MIC values (μg/ml)	Reference antibioticsMIC values (μg/ml)

CSBt	CSEA	Amox	Gent	Vanc

Gram – bacteria

Escherichia coli T20A2	NA	NA	S	R	R

Pseudomonas aeruginosa T41	NA	NA	R	S	R

Pseudomonas aeruginosa ATCC9027	NA	NA	R	S	R

Gram + bacteria

Dermabacter hominis T47A7	312	625	R	S	S

Dermabacter hominis T49B5	312	625	S	S	S

Corynebacterium striatum T40A3	NA	NA	R	R	S

Corynebacterium striatum T46C1	NA	NA	S	S	S

Enterococcus faecalis T37B1	NA	NA	S	S	S

Enterococcus faecalis T47A16	NA	NA	R	S	S

Streptococcus agalactiae T53A4	NA	NA	R	R	R

Staphylococcus aureus T2510	312	625	R	S	S

Staphylococcus aureus T281	NA	NA	R	S	S

Staphylococcus aureus 8143	312	625	S	S	S

Staphylococcus aureus 8148	312	625	R	S	S

Staphylococcus aureus 8142	NA	NA	R	S	S

Staphylococcus aureus T61	NA	NA	R	S	S

Staphylococcus aureus T21	312	625	R	S	S

Staphylococcus aureus T11	NA	NA	R	S	S

Staphylococcus aureus T306	312	625	S	S	S

Staphylococcus aureus T26A4	625	625	R	S	S

Staphylococcus epidermidis T151	NA	NA	R	R	S

Staphylococcus epidermidis T19A1	NA	NA	S	S	R

Staphylococcus capitis T21A3	NA	NA	S	S	S

Staphylococcus capitis T29A2	NA	NA	S	S	S

Staphylococcus pettenkoferi T282	NA	NA	S	S	S

Staphylococcus pettenkoferi T33	NA	NA	R	S	S

Staphylococcus saprophyticus 8237 	NA	NA	S	S	S

Staphylococcus lugdunensis T36A1	NA	NA	S	S	S

Staphylococcus lugdunensis T47B2	NA	NA	S	S	S

	Active partitions MIC values (μg/ml)	Reference antibioticsMIC values (μg/ml)

CSBt	CSEA	Amox	Gent

Gram – bacteria

Escherichia coli T20A2	NA	NA	S	R

Pseudomonas aeruginosa T41	NA	NA	R	S

Pseudomonas aeruginosa ATCC9027	NA	NA	R	S

Gram + bacteria

Dermabacter hominis T47A7	312	625	R	S

Dermabacter hominis T49B5	312	625	S	S

Corynebacterium striatum T40A3	NA	NA	R	R

Corynebacterium striatum T46C1	NA	NA	S	S

Enterococcus faecalis T37B1	NA	NA	S	S

Enterococcus faecalis T47A16	NA	NA	R	S

Streptococcus agalactiae T53A4	NA	NA	R	R

Staphylococcus aureus T2510	312	625	R	S

Staphylococcus aureus T281	NA	NA	R	S

Staphylococcus aureus 8143	312	625	S	S

Staphylococcus aureus 8148	312	625	R	S

Staphylococcus aureus 8142	NA	NA	R	S

Staphylococcus aureus T61	NA	NA	R	S

Staphylococcus aureus T21	312	625	R	S

Staphylococcus aureus T11	NA	NA	R	S

Staphylococcus aureus T306	312	625	S	S

Staphylococcus aureus T26A4	625	625	R	S

Staphylococcus epidermidis T151	NA	NA	R	R

Staphylococcus epidermidis T19A1	NA	NA	S	S

Staphylococcus capitis T21A3	NA	NA	S	S

Staphylococcus capitis T29A2	NA	NA	S	S

Staphylococcus pettenkoferi T282	NA	NA	S	S

Staphylococcus pettenkoferi T33	NA	NA	R	S

Staphylococcus saprophyticus 8237	NA	NA	S	S

Staphylococcus lugdunensis T36A1	NA	NA	S	S

Staphylococcus lugdunensis T47B2	NA	NA	S	S

Reference antibioticsMIC values (μg/ml)

Vanc

R

R

R

S

S

S

S

S

S

R

S

S

S

S

S

S

S

S

S

S

S

R

S

S

S

S

S

S

S


Credit Points(Score)	Class	Premium Reduction	Number of LouisianaParishes

(SFHA)	Non-SFHA


	Species

Habitat characteristics	An. arabiensis	An. chrysti	An. cinereus	An. demeilloni

Correlation


SNV	bp	Conserved Regiona	P-Valueb	Allelesc	MAFd	Unaffected	Scoliosis	Kyphoscoliosis

rs114080324	2947499	Yes	0.116	G/A	0.006	GG	GG	GG	—	GG	AG	AG	AG	AG	AG

rs183225473	3045672	No	0.039	G/C	0.006	GG	GG	GG	CG	GG	CG	CG	CG	CG	CG

rs10068728	3045983	Yes	0.034	T/G	0.27	TT	TT	TT	TG	TT	—	TG	TG	TG	TG

rs146531224	3046004	No	0.039	G/A	0.006	GG	GG	GG	AG	GG	AG	AG	AG	AG	AG

rs117273909	3182971	Yes	0.039	C/T	0.005	CC	CC	CC	CT	CC	CT	CT	CT	CT	CT

rs111916055	3187995	No	0.034	A/G	0.028	AA	AA	AA	AG	AA	—	AG	AG	AG	AG

Novel	3188045	No	0.083	T/G	NA	TT	TT	TT	AT	TT	—	AT	AT	—	AT

rs16871553	3269602	No	0.029	C/T	0.109	TT	TT	TT	CT	TT	CT	CT	CT	CT	—

rs73733752	3278780	No	0.039	A/G	0.03	AA	AA	AA	AG	AA	AG	AG	AG	AG	AG


	Total number of patients(n = 376)

Trials

 Ludman [27]	40 (11%)

 Crimi [28]	76 (20%)

 Garcia-Dorado [30]	177 (47%)

 White [29]	83 (22%)

Randomization

 Intervention	191 (51%)

 Placebo	185 (49%)

Age	59 ± 12

Sex — male	193 (51%)

Risk factors

 Smoking	221 (59%)

 Hypertension	166 (44%)

 Dyslipidemia	117 (31%)

 Diabetes Mellitus	55 (15%)

 Family history of CAD	72 (19%)

 Pre-infarct angina	108 (29%)

Onset to balloon time/min	215 ± 97

Artery involved

 LAD	211 (56%)

 RCA	71 (19%)

 Cx	94 (25%)

TIMI flow pre-PPCI

 0	365 (97%)

 1	11 (3%)

Rentrop collateral flow

 0	287 (76%)

 1	61 (16%)

 2	28 (7%)

TIMI flow post-PPCI

 1	1 (1%)

 2	43 (11%)

 3	330 (88%)

CMR details

 LVEDV	154 ± 36

 LVESV	78 ± 31

 LVEF	50 ± 11

 MI size/%LV	22 ± 11

 AAR/%LV	33 ± 12

 MI size/%AAR	64 ± 21

 MVO/%	111 (53%)

	Total number of patients(n = 376)

LVESV	78 ± 31

LVEF	50 ± 11

MI size/%LV	22 ± 11

AAR/%LV	33 ± 12

MI size/%AAR	64 ± 21

MVO/%	111 (53%)


Probe Set ID	Gene Title	Gene Symbol	FC in tumors	GO biological function

99104_at	adiponectin, C1Q and collagen domain containing	Adipoq	-21.75	Lipid metabolism, Organic acid metabolism

99671_at	adipsin	Adn	-35.98

98924_at	ADP-ribosyltransferase 3	Art3	-2.55

92537_g_at	adrenergic receptor, beta 3	Adrb3	-2.88

102327_at	amine oxidase, copper containing 3	Aoc3	-3.66	Cell adhesion

96785_at	ankyrin repeat domain 47	Ankrd47	-2.04

104761_at	anthrax toxin receptor 2	Antxr2	-1.60

160375_at	carbonic anhydrase 3	Car3	-20.83

101539_f_at	carboxylesterase 3	Ces3	-4.06	Lipid metabolism, Organic acid metabolism

102016_at	cell death-inducing DFFA-like effector c	Cidec	-4.79

95415_f_at	complement component 1, r subcomponent	C1r	-2.64

92224_at	C-type lectin domain family 3, member b	Clec3b	-5.87

96346_at	cysteine dioxygenase 1, cytosolic	Cdo1	-9.76	Organic acid metabolism

93996_at	cytochrome P450, family 2, subfamily e, polypeptide 1	Cyp2e1	-3.54

96742_at	dermatopontin	Dpt	-5.06	Cell adhesion

103031_g_at	dynamin 1	Dnm1	-2.21

92535_at	early B-cell factor 1	Ebf1	-1.81

100567_at	fatty acid binding protein 4, adipocyte	Fabp4	-2.31

92441_at	fibroblast activation protein	Fap	-2.27

101991_at	flavin containing monooxygenase 1	Fmo1	-3.20

93040_at	FXYD domain-containing ion transport regulator 1	Fxyd1	-2.69

93750_at	gelsolin	Gsn	-5.43

102373_at	glutamyl aminopeptidase	Enpep	-2.86

99108_s_at	growth hormone receptor	Ghr	-1.99

92833_at	histidine ammonia lyase	Hal	-2.25	Organic acid metabolism

95546_g_at	insulin-like growth factor 1	Igf1	-2.07

103904_at	insulin-like growth factor binding protein 6	Igfbp6	-4.34

92366_at	laminin, alpha 2	Lama2	-3.25	Cell adhesion

103083_at	lipase, hormone sensitive	Lipe	-2.46	Lipid metabolism

160083_at/95611_at	lipoprotein lipase	Lpl	-5.18	Lipid metabolism

93353_at	lumican	Lum	-9.33

97520_s_at	neuronatin	Nnat	-5.92

100120_at	nidogen 1	Nid1	-2.19	Cell adhesion

160481_at	phosphoenolpyruvate carboxykinase 1, cytosolic	Pck1	-2.61	Lipid metabolism, Organic acid metabolism

102763_at	plasma membrane associated protein, S3-12	MGI:1929709	-8.13

93826_at	protein phosphatase 2, regulatory subunit B (B56), alpha isoform	Ppp2r5a	-1.43

102366_at	resistin	Retn	-10.89

97835_at	retinoic acid receptor responder (tazarotene induced) 2	Rarres2	-6.19

96047_at	retinol binding protein 4, plasma	Rbp4	-4.08

104445_at	RIKEN cDNA 4631408O11 gene	4631408O11Rik	-5.20

101861_at	sarcoglycan, epsilon	Sgce	-1.62

102707_f_at	serine (or cysteine) peptidase inhibitor, clade A, member 3C	Serpina3c	-1.94

97429_at	SNF related kinase	Snrk	-1.65

92582_at	solute carrier family 1 (neutral amino acid transporter), member 5	Slc1a5	-1.94

160320_at	sorbin and SH3 domain containing 1	Sorbs1	-2.74	Cell adhesion

94056_at/94057_g_at	stearoyl-Coenzyme A desaturase 1	Scd1	-2.76	Lipid metabolism, Organic acid metabolism

103087_at	sulfotransferase family 1A, phenol-preferring, member 1	Sult1a1	-1.68	Lipid metabolism

103568_at	sushi-repeat-containing protein	Srpx	-2.84

104280_at	synuclein, gamma	Sncg	-4.63

102916_s_at/161907_s_at	tenascin XB	Tnxb	-4.73	Cell adhesion

160547_s_at	thioredoxin interacting protein	Txnip	-2.83

99052_at	zinc finger homeobox 1a	Zfhx1a	-1.63

Probe Set ID	Gene Title	Gene Symbol	FC in tumors	GO biological function

101539_f_at	carboxylesterase 3	Ces3	-4.06	Lipid metabolism, Organic acid metabolism

102016_at	cell death-inducing DFFA-like effector c	Cidec	-4.79

95415_f_at	complement component 1, r subcomponent	C1r	-2.64

92224_at	C-type lectin domain family 3, member b	Clec3b	-5.87

96346_at	cysteine dioxygenase 1, cytosolic	Cdo1	-9.76	Organic acid metabolism

93996_at	cytochrome P450, family 2, subfamily e, polypeptide 1	Cyp2e1	-3.54

96742_at	dermatopontin	Dpt	-5.06	Cell adhesion

103031_g_at	dynamin 1	Dnm1	-2.21

92535_at	early B-cell factor 1	Ebf1	-1.81

100567_at	fatty acid binding protein 4, adipocyte	Fabp4	-2.31

92441_at	fibroblast activation protein	Fap	-2.27

101991_at	flavin containing monooxygenase 1	Fmo1	-3.20

93040_at	FXYD domain-containing ion transport regulator 1	Fxyd1	-2.69

93750_at	gelsolin	Gsn	-5.43

102373_at	glutamyl aminopeptidase	Enpep	-2.86

99108_s_at	growth hormone receptor	Ghr	-1.99

92833_at	histidine ammonia lyase	Hal	-2.25	Organic acid metabolism

95546_g_at	insulin-like growth factor 1	Igf1	-2.07

103904_at	insulin-like growth factor binding protein 6	Igfbp6	-4.34

92366_at	laminin, alpha 2	Lama2	-3.25	Cell adhesion

103083_at	lipase, hormone sensitive	Lipe	-2.46	Lipid metabolism

160083_at/95611_at	lipoprotein lipase	Lpl	-5.18	Lipid metabolism

93353_at	lumican	Lum	-9.33

97520_s_at	neuronatin	Nnat	-5.92

100120_at	nidogen 1	Nid1	-2.19	Cell adhesion

160481_at	phosphoenolpyruvate carboxykinase 1, cytosolic	Pck1	-2.61	Lipid metabolism, Organic acid metabolism

102763_at	plasma membrane associated protein, S3-12	MGI:1929709	-8.13

93826_at	protein phosphatase 2, regulatory subunit B (B56), alpha isoform	Ppp2r5a	-1.43

102366_at	resistin	Retn	-10.89

97835_at	retinoic acid receptor responder (tazarotene induced) 2	Rarres2	-6.19

96047_at	retinol binding protein 4, plasma	Rbp4	-4.08

104445_at	RIKEN cDNA 4631408O11 gene	4631408O11Rik	-5.20

101861_at	sarcoglycan, epsilon	Sgce	-1.62

102707_f_at	serine (or cysteine) peptidase inhibitor, clade A, member 3C	Serpina3c	-1.94

97429_at	SNF related kinase	Snrk	-1.65

92582_at	solute carrier family 1 (neutral amino acid transporter), member 5	Slc1a5	-1.94

160320_at	sorbin and SH3 domain containing 1	Sorbs1	-2.74	Cell adhesion

94056_at/94057_g_at	stearoyl-Coenzyme A desaturase 1	Scd1	-2.76	Lipid metabolism, Organic acid metabolism

103087_at	sulfotransferase family 1A, phenol-preferring, member 1	Sult1a1	-1.68	Lipid metabolism

103568_at	sushi-repeat-containing protein	Srpx	-2.84

104280_at	synuclein, gamma	Sncg	-4.63

102916_s_at/161907_s_at	tenascin XB	Tnxb	-4.73	Cell adhesion

160547_s_at	thioredoxin interacting protein	Txnip	-2.83

99052_at	zinc finger homeobox 1a	Zfhx1a	-1.63


	STX	Okadaic Acid, DTXS	Domoic Acid

(PSP)	(DSP)	(ASP)

Sampling Date	Multi SPR	ELISA	Multi SPR	ELISA	Multi SPR	ELISA

24.07.2011	−	−	−	−	−	−

08.08.2011	−	−	−	+	−	−

22.08.2011	−	+	−	+	−	−

04.10.2011	−	+	−	+	−	+

20.10.2011	+	+	−	+	−	+


Vitamin D Status	IOM	Endocrine Society

Deficiency	<12 ng/mL (30 nmol/L)	<20 ng/mL (50 nmol/L)

Insufficiency	12–20 ng/mL (30–50 nmol/L)	21–29 ng/mL (52.5–72.5 nmol/L)

Sufficiency	>20 ng/mL (50 nmol/L)	>30 ng/mL (75 nmol/L)

Toxicity	>50 ng/mL (125 nmol/L)	>150 ng/mL (375 nmol/L)

Vitamin D Status	IOM	Endocrine Society

Sufficiency	>20 ng/mL (50 nmol/L)	>30 ng/mL (75 nmol/L)

Toxicity	>50 ng/mL (125 nmol/L)	>150 ng/mL (375 nmol/L)


weats		2			1	0	0

Rash/Hives	15	4	4	2	2	2	1	0

Swelling of eye/face	1	1	0	0	0	0	0	0

Anxiety	6	6	0	0	0	0	0	0

Treatment

Observation	30	14	3	2	5	1	2	3

Antihistamines	18	4	3	2	4	1	3	1

Steroids	14	3	1	2	3	2	3	0

Adrenaline	2	2	0	0	0	0	0	0


Gene Symbol	Primary Sertoli cell signal (normalized)	hS1 cell signal (normalized)	Log2 FC (hS1 vs. Control)

GATA4	10.017227	9.562365	–0.4548

GATA1	2.7784665	2.5375004	–0.2409661


No	Expression system	SAK Productivity [mg/Lbroth]	Cultivation system	Volume [L]	SAK - glycosylation [Yes/No]	Reference

1	E. coli	> 50	(not defined)	2.7	No	[8]

2	E. coli	> 175	Fermenter	10-15	No	[19]

3a	B. subtilis	140	Shake flask	0.25	No	[20]

3b	B. subtilis	337	Fermenter	2	No	[20]

4a	P.pastoris	110	Fermenter	< 5	Partially yes	[13]

4b	E. coli	300-400	Shake flask	0.1	No	[13]

5	E. coli	2800	Fermenter	2	No	[21]

6	P.pastoris	~ 1000	Shake flask (w/o -tunicamycin)	0.05	Yes	[17]

7	P.pastoris	 	Shake flask (w - tunicamycin)	0.05	No	[17]

8	H. polymorpha	~ 1100	Fermenter	80	No	-

No	Expression system	SAK Productivity [mg/Lbroth]	Cultivation system	Volume [L]	SAK - glycosylation [Yes/No]

1	E. coli	> 50	(not defined)	2.7	No

2	E. coli	> 175	Fermenter	10-15	No

3a	B. subtilis	140	Shake flask	0.25	No

3b	B. subtilis	337	Fermenter	2	No

4a	P.pastoris	110	Fermenter	< 5	Partially yes

4b	E. coli	300-400	Shake flask	0.1	No

5	E. coli	2800	Fermenter	2	No

6	P.pastoris	~ 1000	Shake flask (w/o -tunicamycin)	0.05	Yes

7	P.pastoris		Shake flask (w - tunicamycin)	0.05	No

8	H. polymorpha	~ 1100	Fermenter	80	No


Length of training (months)	Total hours of training	Year

22	2996	1989

23	3672	1996

19.5	2719	2001

23	3341	2007

Length of training (months)	Total hours of training	Year

19.5	2719	2001

23	3341	2007


Provinces	No. of samples

	Bovine	Ovine	Caprine	Buffalo	Camel

Tehran	274	100	53	165	33

Isfahan	188	76	148	70	81

Kerman	83	152	102	25	70

Khorasan	75	197	139	112	30

Total	620	525	442	372	214

Provinces	No. of samples

	Bovine	Ovine	Caprine

Tehran	274	100	53

Isfahan	188	76	148

Kerman	83	152	102

Khorasan	75	197	139

Total	620	525	442


Number of strain/strain code	Species	Biofilm	Cefoxitin resistance

65/ MSSE 65	S.epidermidis	black (+)	S

62/ MRSE 62	S.epidermidis	black (+)	R

93/ MSSH 93	S.haemolyticus	bordeaux (−)	S

89/MRSH 89	S.haemolyticus	bordeaux (−)	R

ATCC 12493	S. aureus	very black (+)	R

Number of strain/strain code	Species	Biofilm	Cefoxitin resistance

65/ MSSE 65	S.epidermidis	black (+)	S

62/ MRSE 62	S.epidermidis	black (+)	R

93/ MSSH 93	S.haemolyticus	bordeaux (−)	S

89/MRSH 89	S.haemolytic	bor	R

Number of strain/strain code	Species	Biofilm	Cefoxitin resistance

	us	deaux (−)

ATCC 12493	S. aureus	very black (+)	R


Country	Seroprevalence of HCV in general population [1, 63] (%)	Seroprevalencea of HCV in HIV patients (%)

Argentina	1.9	29.9

Brazil	1.4	18.9

Chile	0.8	2.6

Colombia	1.0	0.8

Cuba	1.8	12.9

Mexico	1.0	12.1

Peru	1.0	4.3

Puerto Rico	6.3	5.2

Venezuela	0.9	0.7

Country	Seroprevalence of HCV in general population [1, 63] (%)	Seroprevalencea of HCV in HIV patients (%)

Colombia	1.0	0.8

Cuba	1.8	12.9

Mexico	1.0	12.1

Peru	1.0	4.3

Puerto Rico	6.3	5.2

Venezuela	0.9	0.7


Variable	AQP4(−) NEBLs patients (n=16)	AQP4(+) NEBLs patients (n=37)	P values


	Group

	STZ + DMH	STZ + DMH + MET

N	13	15

Tumor-bearing rats	11	9

Tumor incidence (%)	84.62	60.00

Number of tumors	40	20

Average tumor number	3.1 ± 0.45	1.3 ± 0.37*

Average tumor number of tumor-bearing rats	3.6 ± 0.28	2.2 ± 0.36*

Volume of tumors (mm3)	94.8 ± 19.77	30.9 ± 8.19*

Inhibition of colorectal tumor (%)		29.08


Study design	Study	Comment

Survey	National TB epidemiological survey 200217	45% (121/272) of patients having interrupted or suspended treatment due to financial difficulty

	Zhang 200712	9% of households with TB suspects (2308) or patients defaulted due to financial burden

	Xu 200920	16% (13/82) of non-adherence patients interrupted treatment because of high medical costs of the treatment

	Ai 201022	2% of patients who interrupted treatment (43) because of financial difficulty

Cohort	Jackson 200611	3% (5/159) was too poor to begin treatment

	Sun 200723	Patients who were charged high medical cost were more likely to interrupt treatment than patients having lower medical costs

Study	Comment

National TB epidemiological survey 200217	45% (121/272) of patients having interrupted or suspended treatment due to financial difficulty

Zhang 200712	9% of households with TB suspects (2308) or patients defaulted due to financial burden

Xu 200920	16% (13/82) of non-adherence patients interrupted treatment because of high medical costs of the treatment

Ai 201022	2% of patients who interrupted treatment (43) because of financial difficulty

Jackson 200611	3% (5/159) was too poor to begin treatment

Sun 200723	Patients who were charged high medical cost were more likely to interrupt treatment than patients having lower medical costs


Study	Year published	n	MC/SC	Patients	EN/PN	Gln adm	Daily gln dose	Length of treatment*	Treatment benefit

Andrews [53]	2011	502	MC	General ICU	EN+PN	iv	10-20 g	5 (1-10)	None

Beale [29]	2008	55	SC	General ICU	EN	enteral	40 g	<10	Morbidity

Conejero [46]	2002	84	MC	General ICU	EN	enteral	35 g	10 (7-25)	Morbidity

Garrel [47]	2003	41	SC	Burns	EN	enteral	26 g	30 ± 17	Mortality

Goeters [14]	2002	95	MC	General ICU	EN+PN	iv	0.2 g/kg	17 ± 11	Mortality

Griffiths [15]	1997	84	SC	General ICU	PN	iv	25 g	6 (2-91)	Mortality

Hall [48]	2003	363	SC	General ICU	EN	enteral	11-27 g	10 (6-16)	None

Houdijk [30]	1998	72	SC	Trauma	EN	enteral	27 g	12 ± 6	Morbidity

Jones [49]	1999	50	SC	General ICU	EN	enteral	18 (11-21) g	11 (3-47)	Morbidity

Wernerman [17]	2011	284	MC	General ICU	EN+PN	iv	0.28 g/kg	12 (4-47)	Mortality

Zhou [50]	2003	40	SC	Burns	EN	enteral	0.35 g/kg	12	Morbidity

Study	Year published	n	MC/SC	Patients	EN/PN	Gln adm	Daily gln dose	Length of treatment*	Treatment benefit

Jones [49]	1999	50	SC	General ICU	EN	enteral	18 (11-21) g	11 (3-47)	Morbidity

Wernerman [17]	2011	284	MC	General ICU	EN+PN	iv	0.28 g/kg	12 (4-47)	Mortality

Zhou [50]	2003	40	SC	Burns	EN	enteral	0.35 g/kg	12	Morbidity


	Timing of initial post-discharge outpatient follow up

	Casesn	≤3 daysn (%)	>3 daysn (%)	p-value

Low-risk*

 Short-stay†	34	22 (65)	12 (35)	0.29

 Longer-stay	44	22 (50)	22 (50)

Higher-risk

 Short-stay	21	17 (81)	4 (19)	0.04

 Longer-stay	74	39 (53)	35 (47)

	Timing of initial post-discharge outpatient follow up

	Casesn	≤3 daysn (%)	>3 daysn (%)	p-value

Longer-stay	44	22 (50)	22 (50)	0.29

Higher-risk

Short-stay	21	17 (81)	4 (19)	0.04

Longer-stay	74	39 (53)	35 (47)


Nomenclature	Amino acids	Chromosome	Intracellular localization

Zm2G012631_T01	699	II	Nucleus and mitochondrial matrix space

Zm2G112165_T01	698	II	Nucleus and mitochondrial matrix space

Zm2G069651_T01	699	II	Nucleus and mitochondrial matrix space

Zm5G833699_T01	714	V	Nucleus and mitochondrial matrix space

Zm2G141931_T01	804	II	Endoplasmic reticulum and vacuole

Zm2G141931_T03	710	II	Endoplasmic reticulum and vacuole

Zm2G399073_T02	1001	II	Endoplasmic reticulum

Zm2G399073_T03	808	II	Endoplasmic reticulum

Zm2G141931_T04	667	II	Endoplasmic reticulum

Zm2G002220_T01	793	II	Chloroplast stroma and chloroplast thylakoid membrane

Zm5G813217_T01	758	V	Nucleus and chloroplast stroma

Zm5G813217_T03	708	V	Nucleus and mitochondrial matrix space

Nomenclature	Amino acids	Chromosome	Intracellular localization

Zm5G833699_T01	714	V	Nucleus and mitochondrial matrix space

Zm2G141931_T01	804	II	Endoplasmic reticulum and vacuole

Zm2G141931_T03	710	II	Endoplasmic reticulum and vacuole

Zm2G399073_T02	1001	II	Endoplasmic reticulum

Zm2G399073_T03	808	II	Endoplasmic reticulum

Zm2G141931_T04	667	II	Endoplasmic reticulum

Zm2G002220_T01	793	II	Chloroplast stroma and chloroplast thylakoid membrane

Zm5G813217_T01	758	V	Nucleus and chloroplast stroma

Zm5G813217_T03	708	V	Nucleus and mitochondrial matrix space


Compartment	Local**	Distant**

	sp†	sh†°	cb	ais	?	n (∑)	sp†	sh†°	cb^	ais	?	n (∑)


cDNA	No. of isolates	Characteristics

NIK	58	N terminal deletion

CD30	3	Full length

LT-βR	2	Cytoplasmic region

RIP2	1	Full length


	Cardiac syncope vs non-cardiac syncopen = 142	Cardiac syncope vs chest pain control groupn = 147

Patient characteristics	Cardiac syncopen = 49	Non-cardiacsyncopen = 93	P-value	Cardiac syncopen = 49	Chest paincontrol groupn = 98	P-value

Age, years	60 ± 13	54 ± 12	0.002	60 ± 13	60 ± 12	0.810

Male gender	32 (65)	57 (61)	0.716	32 (65)	64 (65)	>0.999

BMI, kg/m2	26 ± 3	26 ± 4	0.365	26 ± 3	27 ± 4	0.116

Systolic Blood Pressure, mm Hg	143 ± 20	140 ± 21	0.349	143 ± 20	144 ± 16	0.990

Diastolic Blood Pressure, mm Hg	81 ± 13	83 ± 13	0.396	81 ± 13	78 ± 9	0.140

Active smoking	19 (39)	27 (29)	0.256	19 (39)	38 (39)	>0.999

Diabetes mellitus II	3 (6)	4 (4)	0.693	3 (6)	5 (5)	>0.999

Family history of CAD	16 (33)	43 (46)	0.152	16 (33)	27 (28)	0.566

PROCAM risk score	9 (4–21)a	7 (2–16)b	0.131	9 (4–21)a	8 (3–16)	0.280


Main mindfulness instruction	General guidance points	Contemplative movement	Mindful movement

Awareness of sensations	Bodily sensations as objects for the attention (sensations related to autonomic response, skeletal and muscular aspects, pressure, tactile and visceral, proprioception, kinematics)	√	√

Awareness of the present moment (PM)	PM attributes of body, movement sensations, and breath	Implicit	√

PM attribute of mental experience, e.g., emphasis on staying with the present moment (not getting lost in past or future thinking)	Not usually

Awareness of attention	Deliberate awareness of the ways in which to move, shift, narrow, and widen the focus of attention to aspects of body and movement. Commentary on the quality of the attention (vivid, dull, agitated, stable, striving)	Not usually	√

Awareness of mind-wandering	Acknowledgment and suggested management of mind-wandering	Not usually	√

Awareness of intention (on purpose)	Purposeful, deliberate engagement with the intention to move the body, pay attention, be present, mindful	Can be (e.g., Tai Chi, Feldenkrais, continuum movement)	√

Awareness of non-judgment	A deliberate attitude of acceptance and gentleness to mental and physical phenomena. For example, psychological responses to learning new movements (frustration, elation, irritation, pride)	Implicit and in relation to the physical body rather than the mind	√

Main mindfulness instruction	General guidance points	Contemplative movement	Mindful movement

Awareness of intention (on purpose)	Purposeful, deliberate engagement with the intention to move the body, pay attention, be present, mindful	Can be (e.g., Tai Chi, Feldenkrais, continuum movement)	√

Awareness of non-judgment	A deliberate attitude of acceptance and gentleness to mental and physical phenomena. For example, psychological responses to learning new movements (frustration, elation, irritation, pride)	Implicit and in relation to the physical body rather than the mind	√


 Compounds of hydrocarbon	Mean	SD

Pars 1 dispersant	0.126	0.082

 Pars 2 dispersant	0.055	0.049

 Gamlen dispersant	0.011	0.004

 Crude oil	0.072	 0.046

Pars 1 dispersant + petroleum	 0.156	 0.098

Pars 2 dispersant + petroleum	 0.104	 0.087

Gamlen dispersant + petroleum	 0.115	 0.067

Compounds of hydrocarbon	Mean	SD

Pars 1 dispersant	0.126	0.082

Pars 2 dispersant	0.055	0.049

Gamlen dispersant	0.011	0.004

Crude	0.07	0.0

 oil	2	46

Pars 1 dispersant + petroleum	0.156	0.098

Pars 2 dispersant + petroleum	0.104	0.087

Gamlen dispersant + petroleum	0.115	0.067


Categorical variables

	Consented to participate n = 43 (37%)	Declined to participate n = 73 (63%)	All (n = 116)	P-value χ2 test

First degree relative with diabetes mellitus

No	22 (35%)	41 (65%)	63	0.601

Yes	21 (40%)	32 (60%)	53

Smoker

Past	17 (41%)	25 (59%)	42	0.790

Current	7 (39%)	11 (61%)	18

Never	19 (34%)	37 (66%)	56

Meets daily exercise requirements

No	5 (31%)	11 (69%)	16	0.604

Yes	38 (38%)	62 (62%)	100

Meets daily fruit and vegetable requirements

No	0	3(100%)	3	0.178

Yes	43 (38%)	70 (62%)	113

Insulin use during pregnancy

No	33 (46%)	38 (54%)	71	0.008 95% CI (7.5, 41)

Yes	10 (22%)	35 (77%)	45

IFG at follow-up

No	34 (36%)	61 (64%)	95	0.544


Variable	Manipur n = 41	Nagaland n = 33	Total n = 74

dary	)	3)	53)

Tertiary	21 (51)	1 (3)	22 (30)


Baseline	One month after treatment	Three month after treatment


Stages	Classification	Macroscopic appearance	Oocyte size (μm)	GSI range

		Testes	Ovary		F	M

I	Immature	Small, flat, translucent to whitish, poorly developed, with reduced fringes.	Small, transparent to translucent and not very voluminous. Oocyte not visible with naked eye.	209.61-592.78 (447.30 ± 99.42)a	<10.9	<2.0

II	Develop	Whitish with voluminous fringes.	Large orange-pale, oocytes may be visible through the ovary tunic.	528.37-867.10 (711.24 ± 63.21)b	11.0-18.9	2.5-5.5

III	Mature	Very large, firm, white in colour.	Very large occupying part of the abdominal cavity. Yellow oocyte turgescency.	604.15-894.33 (780.59 ± 50.71)c	19.0-23.9	5.6-8.0

IV	Ripe	Full developed, turgid fringes, milky-whitish in colour. Milt run out of the fish.	Occupying the entire abdominal cavity. Ovulated oocytes can be fully expelled from the oviduct with gentle pressure.	725.27-991.81 (844.09 ± 57.59)d	>24.0	> 8.0

V	Spent	Bloody and flaccid fringes.	Flaccid, red-brown or bloody in colour. Few remaining large oocytes observed, and smaller size oocytes may be seen.	227.64-770.82 (447.38 ± 139.02)a	2.5-10.9	1.5-3.0


Biotype	Human	Mouse

LincRNA	13245	6473

Antisense	10980	3612

TEC	1072	2759

Sense_intronic	984	294

Retained_intron	517	294

Processed_transcript	368	980

Sense_overlapping	310	50

3prime_overlapping_ncRNA	34	3

Pseudogene	20	24

Bidirectional_promoter_lncRNA	11	118

Non_coding	3	0

Macro_lncRNA	1	2

Total	27545	14609


	FAF (%)	NIA(%)

	hypoFAF	mixedFAF	hyperFAF	hypoNIA	mixedNIA	hyperNIA

Detached area (N = 10)	10	20	70	30	20	50

Leakage spot (N = 13)	23.1	×	76.9	92.3	×	7.7

Window defect area (N = 8)	12.5	12.5	75	62.5	32.5	0

Overall image (N = 17)	17.6	11.8	70.6	58.8	17.6	23.5

PED (N = 22)				63.6	×	36.4

	FAF (%)	NIA(%)

	hypoFAF	mixedFAF	hyperFAF	hypoNIA	mixedNIA	hyperNIA

Detached area (N = 10)	10	20	70	30	20	50

Leakage sp	23	×	76	92.3

	FAF (%)	NIA(%)

	hypoFAF	mixedFAF	hyperFAF	hypoNIA	mixedNIA	hyperNIA

ot (N = 13)	.1		.9		×	7.7

Window defect area (N = 8)	12.5	12.5	75	62.5	32.5	0

Overall image (N = 17)	17.6	11.8	70.6	58.8	17.6	23.5

PED (N = 22)				63.6	×	36.4


	VAS Measurea	M	SD	95% Confidence Interval	Response Range

Mechanism	Acceptance, equality, and non-judgment	80.1	20.7	[76.83, 83.34]	0–100

	Dignity and self-worth	77.3	21.5	[73.88, 80.65]	1–100

	Reduced experience of stigma	83	20.1	[79.78, 86.15]	10–100

	Independence and self-efficacy	81	19.8	[77.79, 84.04]	8–100

	Relationship to others and reduced isolation	74	23.8	[70.02, 77.63]	0–100

	Sense of connection and belonging	79	21.9	[75.20, 82.24]	0–100

Outcome

	Feeling better and at peace	74	23	[70.31, 77.55]	0–100

	Personhood	83	18.9	[80.00, 85.93]	0–100

	Skills Acquired	75	23.6	[71.53, 79.05]	0–100

	VAS Measurea	M	SD	95% Confidence Interval

Mechanism	Acceptance, equality, and non-judgment	80.1	20.7	[76.83, 83.34]

	Dignity and self-worth	77.3	21.5	[73.88, 80.65]

	Reduced experience of stigma	83	20.1	[79.78, 86.15]

	Independence and self-efficacy	81	19.8	[77.79, 84.04]

	Relationship to others and reduced isolation	74	23.8	[70.02, 77.63]

	Sense of connection and belonging	79	21.9	[75.20, 82.24]

Outcome

	Feeling better and at peace	74	23	[70.31, 77.55]

	Personhood	83	18.9	[80.00, 85.93]

	Skills Acquired	75	23.6	[71.53, 79.05]


Type of strategies	Strategies Medicines	NCMS (China)	National Health Insurance (Ghana)	Jamkesmas (Indonesia)	Seguro Popular (Mexico)

Selection	Formulary	✓	✓	✓	✓

Cost sharing for medicines included in the formulary	✓	✗	✗	✗

Generic substitution	✗	✓	✗	✗

Procurement	Medicines prices negotiation or rebates	✓	✗c	✓	(✓)

Bulk procurement	✓	✓<underline>a</underline>	✓	✓

Generic reference pricing	✗	✓	✗a	✓

Contracting	Fee for service for prescribers	✓

Fixed salary for prescribersa		✓	✓a	✓

Fixed reimbursement rates for medicines	✓	✓	✗	✗

Preferred provider network (accreditation)	✗	✓	✓	✓

Utilization	Standard treatment guidelines	(✓)	✓	✓	✓

Payment for performance	(✓)	✗	✗	✗

Separation of prescribing and dispensing	✓	✓	✓	✓

Disease management programs	✓	No info	✓	✓

Monitoring and evaluation	User satisfaction monitoring	✗	✗	✗	✓

Medicines purchasing monitoring	✓b		✓	✓

Prescription monitoring	✗	✗	✗	✗

Type of strategies	Strategies Medicines	NCMS (China)	National Health Insurance (Ghana)	Jamkesmas (Indonesia)	Seguro Popular (Mexico)

Selection	Formulary	✓	✓	✓	✓

Cost sharing for medicines included in the formulary	✓	✗	✗	✗

Generic substitution	✗	✓	✗	✗

Procurement	Medicines prices negotiation or rebates	✓	✗c	✓	(✓)

Bulk procurement	✓	✓a	✓	✓

Generic reference pricing	✗	✓	✗a	✓

Contracting	Fee for service for prescribers	✓

Fixed salary for prescribersa		✓	✓a	✓

Fixed reimbursement rates for medicines	✓	✓	✗	✗

Preferred provider network (accreditation)	✗	✓	✓	✓

Utilization	Standard treatment guidelines	(✓)	✓	✓	✓

Utilization	Payment for performance	(✓)	✗	✗	✗

Separation of prescribing and dispensing	✓	✓	✓	✓

Disease management programs	✓	No info	✓	✓

Monitoring and evaluation	User satisfaction monitoring	✗	✗	✗	✓

Medicines purchasing monitoring	✓b		✓	✓

Prescription monitoring	✗	✗	✗	✗


Type of epilepsy	No. of patients Males/females	Age ranges	Recording length ranges (mins)	No. of electrodes

General epilepsy	7/1	30–45	20–30	22

Type of epilepsy	No. of patients Males/females

General epilepsy	7/1

Age ranges	Recording length ranges (mins)	No. of electrodes

30–45	20–30	22


	Uncompressed

	Method I

IDR	99.1%

FAR	1.5%

FRR	0.3%

ACC	98.7%


Independent predictor	Subgroup comparisons	Parameter estimate	95% CI	p Value

Patient expectation of change	Completely recover	0

Much improve	5.21	1.80 to 8.61	0.003

Slightly improve	12.43	8.20 to 16.67	<0.001

No change/worse	−0.94	−8.53 to 6.66	0.809

Pain self-efficacy		−0.36	−0.50 to −0.22	<0.001

Number of additional health problems	None	0

One	3.52	0.30 to 6.75	0.032

Two or more	6.62	1.48 to 9.75	0.008

Anxiety or depression	None	0

Moderate	2.19	−0.99 to 5.37	0.177

Extreme	12.02	1.49 to 22.56	0.025

Frequency of pain medication	None/occasional	0

Most/every day/night	3.85	0.61 to 7.09	0.020

Most strenuous exercise	None	0

Mild	−5.53	−10.32 to −0.74	0.024

Moderate	−8.98	−13.86 to −4.11	<0.001

Strenuous	−6.82	−12.17 to −1.47	0.013

Difference between passive and active abduction	0.07	0.004 to 0.142	0.038

Change during scapular facilitation	Yes	0

No	4.93	2.13 to 7.74	0.001

Severity of pain at rest		1.89	1.26 to 2.51	<0.001

Duration of shoulder symptoms (weeks)	0.02	0.01 to 0.03	0.002

Paraesthesia in the arm	No	0

Yes	−10.08	−18.73 to −1.43	0.022

Current employment status	Employed	0

Retired	2.96	0.10 to 6.02	0.058

Unemployed	14.30	7.72 to 20.87	<0.001

Independent predictor	Subgroup comparisons

Patient expectation of change	Completely recover

Much improve

Slightly improve

No change/worse

Pain self-efficacy

Number of additional health problems	None

One

Two or more

Anxiety or depression	None

Moderate

Extreme

Frequency of pain medication	None/occasional

Most/every day/night

Most strenuous exercise	None

Mild

Moderate

Strenuous

Difference between passive and active abduction

Change during scapular facilitation	Yes

No

Severity of pain at rest

Duration of shoulder symptoms (weeks)

Paraesthesia in the arm	No

Yes

Current employment status	Employed

Retired

Unemployed


Platoons	Bangolo	Danané	Kahin	Logoualé	Guezon	BleniMéhouin	Dieouzon	Zoukougbeu	Blotile	Duekoue

1			15		3					0.5

2				14			2	2	2

3	4	4			10

4	10				4	4

5	15				3

Platoons	Bangolo	Danané	Kahin	Logoualé	Guezon	BleniMéhouin	Dieouzon	Zoukougbeu	Blotile	Duekoue

1			15		3					0.5

2				14			2	2	2

3	4	4			10

4	10				4	4

	1				3

Platoons	Bangolo	Danané	Kahin	Logoualé	Guezon	BleniMéhouin	Dieouzon	Zoukougbeu	Blotile	Duekoue

5	5


Characteristics	Male (n = 26) (mean ± SD)a	Female (n = 24) (mean ± SD)a

Continuous variable

 Age (years)	28.2 ± 3.18	30.4 ± 3.67

 Prepregnant body mass index (kg/m2)	22.0 ± 3.43	22.8 ± 4.24

 Gestational age (weeks)	39.0 ± 1.50	38.7 ± 1.49

 Baby birth weight (g)	3,251 ± 382	2,958 ± 393

 Baby birth length (cm)	51.6 ± 2.59	50.9 ± 2.63

 Baby head circumference (cm)	33.9 ± 1.23	33.0 ± 1.46

 Placental weight (g)	629 ± 141	579 ± 184

 Fat content of placenta (%)	0.74 ± 0.12	0.77 ± 0.084

Categorical variable

 Cigarette smoking, n (%)	1 (3.85)	2 (8.33)

 Passive smoking, n (%)	13 (50.0)	11 (45.8)

 Alcohol drinking, n (%)	0 (0.0)	0 (0.0)

 Potential dioxin-exposed occupation, n (%)	0 (0.0)	0 (0.0)

Characteristics	Male (n = 26) (mean ± SD)a	Female (n = 24) (mean ± SD)a

Gestational age (weeks)	39.0 ± 1.50	38.7 ± 1.49

Baby birth weight (g)	3,251 ± 382	2,958 ± 393

Baby birth length (cm)	51.6 ± 2.59	50.9 ± 2.63

Baby head circumference (cm)	33.9 ± 1.23	33.0 ± 1.46

Placental weight (g)	629 ± 141	579 ± 184

Fat content of placenta (%)	0.74 ± 0.12	0.77 ± 0.084

Categorical variable

Cigarette smoking, n (%)	1 (3.85)	2 (8.33)

Passive smoking, n (%)	13 (50.0)	11 (45.8)

Alcohol drinking, n (%)	0 (0.0)	0 (0.0)

Potential dioxin-exposed occupation, n (%)	0 (0.0)	0 (0.0)


Gene	Position TGFBR1 TGFBR2 gene	HGVS names	Protein position	Number of patients	rsSNP number

TGFBR1	Exon 1	c.68_76delCGGCGGCG	p.Ala23Ala	4	rs11466445

 	IVS 7 + 24	c.1255 + 24 G > A	 	2	rs334354

TGFBR2	IVS 3 + 7	c.338 + 7 A > G	 	2	rs1155705

 	IVS 5-4	c.455-4 T > A	 	3	rs11466512

 	Exon 4	c.458delA	p.Lys153	8	rs79375991

Gene	Position TGFBR1 TGFBR2 gene	HGVS names	Protein position	Number of patients	rsSNP number

TGFBR1	Ex	c	p.Ala23		r


Subject	Question

Directions	How would you make the directions more clear/easy to understand?

	What does "in the past month" mean to you?

	When you see "the past month", what days did you include?

Items	In your own words, what do you think this question is asking?

	What does this question mean to you? What did you think of when answering this question?

	Was this question easy to understand? Are there any specific words that are difficult to understand?

	How would you change the words to make it more clear?

	Was this item hard to answer? If yes, why?

	How did you choose your answer?

Domains	In your own words, what do you think this group of questions is asking about?

	How do you think these items are related?

	Are there any questions that do not belong in this group?

ResponseChoices	What do you think about the response choices?

	How would you make the response choices clearer or easier to understand?

OverallAssessment	Are there things that we forgot to ask about that you think are important?

	Overall thoughts/opinions of the questionnaire?

	Anything you would change in the questionnaire as a whole?

Subject	Question

	What does "in the past month" mean to you?

	When you see "the past month", what days did you include?

Items	In your own words, what do you think this question is asking?

	What does this question mean to you? What did you think of when answering this question?

	Was this question easy to understand? Are there any specific words that are difficult to understand?

	How would you change the words to make it more clear?

	Was this item hard to answer? If yes, why?

	How did you choose your answer?

Domains	In your own words, what do you think this group of questions is asking about?

	How do you think these items are related?

	Are there any questions that do not belong in this group?

ResponseChoices	What do you think about the response choices?

	How would you make the response choices clearer or easier to understand?

OverallAssessment	Are there things that we forgot to ask about that you think are important?

	Overall thoughts/opinions of the questionnaire?

	Anything you would change in the questionnaire as a whole?


References	Period of sample collection	Year of publication	Study area	Age of participants

Chandenier et al. [20]	1993	1995	Brazzaville, Niari, Kouilou, Pool	6–10 years

Durand et al. [21]	1998	2003	Pointe-Noire	No limit

Nsimba et al. [22]	1999–2002	2004	Brazzaville, Pointe-Noire	0.5–<5 years

Nsimba et al. [23]	1999–2002	2005	Brazzaville, Pointe-Noire	0.5–<5 years

Mayengue et al. [24]	2003	2005	Brazzaville	≤5 years

Ndounga et al. [25]	2003–2004	2007	Brazzaville	<5 years

Ndounga et al. [13]	2003–2006	2008	Brazzaville	No limit

Van den Broek et al. [26]	2004	2006	Kindamba	0.5–<5 years

Mayengue et al. [27]	2005	2011	Brazzaville	No limit

Ndounga et al. [28]	2005	2013	Brazzaville	No limit

Pradine et al. [29]	2005–2006	2006	Pointe-Noire	1.4–17 years

Tsumori et al. [11]	2005–2006	2011	Brazzaville, Gamboma, Pointe-Noire	No limit

Oguike et al. [19]	2005–2006	2011	Brazzaville, Gamboma, Pointe-Noire	No limit

Moyen et al. [14]	2006	2010	Brazzaville	≤15 years

Ndounga et al. [30]	2006	2012	Brazzaville	0.5–10 years

Murai et al. [31]	2006	2015	Brazzaville, Gamboma, Pointe-Noire	No limit

Mita et al. [32]	2006	2016	Brazzaville, Gamboma, Pointe-Noire	No limit

Culleton et al. [12]	2007	2009	Pointe-Noire	No limit

Koekemoer et al. [33]	2009	2011	Boutoto	Not applicable

Koukouikila-Koussounda et al. [15]	2010	2012	Brazzaville	<10 years

Ibara-Okabande et al. [34]	2010–2011	2012	Brazzaville	<10 years

Ndounga et al. [35]	2010–2011	2015	Brazzaville	<10 years

Ossou-Nguiet et al. [18]	2011	2013	Brazzaville	0.4–14 years

Mbongo et al. [17]	2011–2013	2015	Brazzaville	15–39 years

Ntoumi et al. [9]	2011–2012	2013	Brazzaville, Pointe-Noire	≤15 years

Koukouikila-Koussounda et al. [36]	2012–2013	2015	Brazzaville	12–44 years

 Ntoumi et al. [16]	2012–2013	2016	Brazzaville	12–44 years

Singana et al. [10]	2012–2013	2016	Owando	<12 years


n = 1450	Cluster 1n = 385	Cluster 2n = 431	Cluster 3n = 243	Cluster 4n = 391

Severity∧

(i) Moderate	23.8	25.3	31.2	49.4

(ii) Severe	16.8	9.1	8.2	23.1


	SAR	SEM

Coef.	z-Value	Coef.	z-Value

Household car ownership	0.35⁎⁎⁎	5.58	0.22⁎⁎⁎	3.42

Prop. of people going to work by public transport	0.39⁎	2.56	0.42⁎⁎	2.92

Prop. of people who are economically active	0.78⁎	2.57	1.07⁎⁎⁎	3.85

Prop. of white	0.22	1.93	0.22⁎	2.06

Median age	0.01⁎⁎⁎	3.91	0.02⁎⁎⁎	7.00

Prop. of households classified as deprived	− 0.01	− 0.06	− 0.19	− 0.98

Fuel poverty	− 0.004	− 0.84	− 0.002	− 0.45

Regions

 London	Reference case

 East Midlands	0.29⁎⁎⁎	4.93	0.02	0.32

 East of England	0.11⁎	2.10	0.02	0.44

 North East	0.11	1.65	0.03	0.51

 North West	0.09	1.70	− 0.09	− 1.41

 South East	0.10⁎	2.01	0.04	0.73

 South West	0.13⁎	2.20	0.06	1.00

 West Midlands	0.13⁎	2.21	− 0.10	− 1.53

 Yorkshire and the Humber	0.20⁎⁎⁎	3.40	0.03	0.55

Constant	− 0.39	− 1.00	− 0.83⁎	− 2.33

λ	− 55.35⁎⁎⁎	− 3.64

ρ			550.47⁎⁎⁎	30.75

Statistics

 N	320		320

 Log-likelihood	247.75		278.91

 AIC	− 459.49		− 521.81

	SAR	SEM

Coef.	z-Value	Coef.	z-Value

Yorkshire and the Humber	0.20⁎⁎⁎	3.40	0.03	0.55

Constant	− 0.39	− 1.00	− 0.83⁎	− 2.33

λ	− 55.35⁎⁎⁎	− 3.64

ρ			550.47⁎⁎⁎	30.75

Statistics

N	320		320

Log-likelihood	247.75		278.91

AIC	− 459.49		− 521.81


S. No.	Allergen	Mouse MHC class I	Mouse MHC class II	Human MHC class I	Human MHC class II

1	Asp f1	148–156 (VIYTYPNKV)	 	147–155 (RVIYTYPNK)

 	 	 	9–23 (LLAATAVSVLAAPSP)	9–17 (LLAATAVSV)	1–15 (MVAIKNLFLLAATAV)

2	Asp f2	 	5–19 (LRLAVLLPLAAPLVA)	9–17 (VLLPLAAPL)	4–18 (LLRLAVLLPLAAPLV)

3	Asp f5	 	318–332 (LSFKYPYSVSSSPPS)	316–324 (SSLSFKYPY)	308–322 (LNNYRPSSSSLSFKY)

 	 	 	319–333 (SFKYPYSVSSSPPSS)	314–322 (SSSSLSFKY)	305–319 (PSYLNNYRPSSSSLS)

4	Asp f17	 	93–108 (DKFVAANAGGTVYED)	98–106 (AANAGGTVY)

5	Asp f34	 	75–89 (IQDGSLYLYAASATP)	74–82 (YIQDGSLYL)

S. No.	Allergen	Mouse MHC class I

1	Asp f1	148–156 (VIYTYPNKV)

2	Asp f2

3	Asp f5

4	Asp f17

5	Asp f34

Mouse MHC class II	Human MHC class I	Human MHC class II

	147–155 (RVIYTYPNK)

9–23 (LLAATAVSVLAAPSP)	9–17 (LLAATAVSV)	1–15 (MVAIKNLFLLAATAV)

5–19 (LRLAVLLPLAAPLVA)	9–17 (VLLPLAAPL)	4–18 (LLRLAVLLPLAAPLV)

318–332 (LSFKYPYSVSSSPPS)	316–324 (SSLSFKYPY)	308–322 (LNNYRPSSSSLSFKY)

319–333 (SFKYPYSVSSSPPSS)	314–322 (SSSSLSFKY)	305–319 (PSYLNNYRPSSSSLS)

93–108 (DKFVAANAGGTVYED)	98–106 (AANAGGTVY)

75–89 (IQDGSLYLYAASATP)	74–82 (YIQDGSLYL)


Patient sizes	Typical nasal trumpet sizes (Fr)

Large man	34, 30

Medium man	32, 28

Small man	30, 28

Large woman	32, 28

Medium woman	30, 28

Small woman	28, 26


	LN-ER/PR+Her2- status	LN+ER/PR-Her2+ status

	Relapse	No relapse	Relapse	No relapse

Number of patients	12	81	39	51


True Phylo	QuartetS	QuartetA	QuartetM	Quartet-Net	Neighbor-Net	Neighbor-Joining

Sp	Wei	Spli		B		Wei	BV	Spli			Spl				Wei	B	Spli		B


Full Sample	Sibling Subsample	Non-Sibling Subsample


Coefficient	Robust Std.Err.	P > |z|	95% confidence interval